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Abstract 
THE NITRIC OXIDE DONOR MOLSIDOMINE SHOWS THERAPEUTIC BENEFIT TOWARD 
MUSCLE REPAIR AFTER AN ACUTE IMPACT INJURY, IN RATS. 
Background: Muscle injuries are highly prevalent and arise from a multitude of situations. Trauma 
to the soft tissue is painful and debilitating and it requires extensive healing that often involves the 
formation of a fibrotic scar. Current treatments are merely management strategies, such as the RICE 
principle. Nitric oxide (NO) knock-out models show reduced skeletal muscle regeneration and 
excessive fibrosis (Filippin et al., 2011 a & b), suggesting therapeutic promise for NO. NO-donation 
has shown therapeutic promise in mouse models of muscular dystrophy, and therefore, may be 
beneficial for the treatment of acute muscle injuries. 
Objective: To clarify the role of treatment-derived NO on muscle trauma, using the NO-donating 
drug: Molsidomine (MOLS), which has been approved for use in humans.  
Methods: Using a crush injury model in rats, placebo (PLA) or MOLS treatments were administered 
immediately and one day after the injury. MPO, MyoD, myogenin, fibronectin and TGF-β1 protein 
content in the injured tissue homogenates was assessed with Western blots. Collagen deposition at 
21 days after injury was assessed using a Masson’s trichrome stain. 
Results: With MOLS, there was significantly less collagen deposition (p < 0.05) 21 days after injury, 
which was supported by less TGF-β1 protein (p = 0.01) and less fibronectin protein (p < 0.005) 
compared to the PLA group at this time point. Additionally, MOLS tended to modulate the amount 
of MPO and, therefore, the inflammatory response by 33% 5 days after injury.  
Conclusion: MOLS treatment improves, and potentially hastens, tissue repair after an acute impact 
injury through the reduction of excessive fibrosis, as well as through enhanced clearance of 
inflammatory radicals from injured muscle. 
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Uittreksel 
DIE STIKSTOFOKSIEDSKENKER MOLSIDOMIEN TOON TERAPEUTIESE VOORDELE VIR 
SPIERHERSTEL NA ‘N AKUTE IMPAKBESERING IN ROTTE 
Agtergrond: Spierbeserings is baie algemeen en ontstaan as gevolg van verskeie oorsake. Trauma 
aan sagteweefsel is pynlik en benadeel funksie, en dit benodig omvattende genesing wat soms met 
die vorming van fibrotiese letsels gepaard gaan.  Tans word behandeling gerig op beheerstrategieë 
deur gebruik te maak van die “RICE” beginsel.  Stikstofoksied (NO) geen-uitklopmodelle toon aan 
dat daar ‘n verlaging in skeletspierregenerasie is en oormatige fibrose ontstaan (Filippin et al., 2011 
a & b), wat daarop dui dat daar ‘n terapeutiese voordeel vir NO kan wees.  In spierdistrofie 
muismodelle hou NO-skenking  terapeutiese voordele in  en kan dus potensieel ook voordelig wees 
in die behandeling van akute spierbeserings.   
Doelwit: Om duidelikheid te kry oor die rol van behandelings-afgeleide NO in spiertrauma deur 
van die NO-skenkingsmiddel, Molsidomien (MOLS), wat goedgekeur is vir menslike inname, 
gebruik te maak. 
Metode: Deur van ‘n vergruisingsbesering-rotmodel gebruik te maak, is ‘n plasebo (PLA) of MOLS 
behandeling direk, asook na een dag na besering, toegepas. MPO, MyoD, miogenien, fibronektien 
en TGF-β1 proteïeninhoud in ‘n homogene oplossing van die beskadigde weefsel is deur Westerse 
blattering ondersoek. Kollageen neersetting teen 21 dae na besering is deur middel van Masson se 
trichroomkleuring ondersoek. 
Resultate: Behandeling met MOLS het betekenisvol minder kollageen neersetting tot gevolg gehad 
(p < 0.05) teen 21 dae na besering, watverder bevestig is deur minder TGF-β1 proteïen (p = 0.01) en 
fibronektien proteïen (p < 0.005) vergeleke met die PLA groep by dieselfde tydpunt. Boonop het 
MOLS ook geneig om die hoeveelheid MPO – en dus die inflammatoriese respons - met 33% 
verminder, teen vyf dae na besering.  
Gevolgtrekking: MOLS behandeling verbeter, en versnel moontlik, weefselherstel na ‘n akute 
impakbesering deur oormatige fibrose te verminder, en ook deur middel van verbeterde 
verwydering van inflammatoriese radikale uit die beseerde spierweefsel.   
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Chapter 1: Introduction 
A contusion injury is described as a blunt force trauma to an area of soft tissue, resulting in 
devastation of the musculature, which often manifests as a debilitating and painful injury that 
requires a lengthy healing period (Alessandrino & Balconi, 2013). These injuries may arise from a 
multitude of situations including most sporting activities, mishaps in the workplace, motor vehicle-
related accidents and in war or civil unrest, to name a few. The duration of the healing period 
depends on the severity of the injury, and this is where therapeutic efforts have been directed, as the 
concept of speeding up recovery is attractive in many respects. Furthermore, optimal healing of the 
damaged muscle through regeneration and return to normal muscle architecture with minimal scar 
tissue formation, or fibrosis, is important. 
Much work has gone into devising therapies that target traumatic muscle injuries, however, it seems 
the only agreed upon strategy is to apply the RICE principle – rest, ice, compression, elevation - 
immediately after the injury (Järvinen et al., 2013). Non-steroidal anti-inflammatory drugs (NSAIDs) 
are possibly the most widely prescribed and utilised treatment for injuries, especially among injured 
athletes (Tscholl et al., 2008; Warden, 2009), however, it has been suggested that they be taken at the 
lowest dose and for the shortest period possible (Fine, 2013). This is because NSAID use has been 
associated with impaired tendon healing (Dimmen et al., 2009), an elevated risk of re-injury after 
healing (Warden et al., 2006) and even reduced satellite cell activity (Mackey et al., 2007), whilst 
NSAID use in the chronic setting increases the probability of gastrointestinal bleeding (Wallace, 
1994), potentially causing unnecessary mortality through infection. Thus, extreme modulation or 
inhibition of the normal inflammatory response to damage at any time may not be the answer.  
Although not many, some treatment strategies have been aimed at the fibrotic response to injury. 
Muscle heals, in part, by forming a connective tissue scar (Järvinen et al., 2005) which manifests as a 
solid structure that may interfere with the muscle’s functional recovery (Gharaibeh et al., 2012), and 
may also be associated with recurrent muscle tears upon return to activity (Kujala et al., 1997). Some 
antifibrotic therapies such as decorin (Foster et al., 2003; Fukushima et al., 2006) or γ-interferon 
(Foster et al., 2003) have shown promise, but none has a proven evidence-base for clinical use as of 
yet. 
It is quite possible that a dynamic therapeutic approach is required for the treatment of muscle 
injuries, as injury manifestation itself is a multi-faceted process, combining the skeletal muscle, 
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inflammatory and circulatory systems. Nitric oxide (NO) is a multi-functional molecule, known for 
its potent vasodilatory properties, which are exploited and used to treat many cardiovascular 
conditions, such as angina (Messin et al., 2006). NO-based therapies slow down disease progression 
in mouse models of Duchenne Muscular Dystrophy (Wehling et al., 2001; Zordan et al., 2013; Cordani 
et al., 2014), affecting multiple mediators in this complex disease and ultimately improving the 
skeletal muscle phenotype. Inhibiting NO-signalling appears to impair muscle growth and function 
(de Palma et al., 2014). Additionally, in the context of experimental muscle damage, NO-signalling 
inhibition has a negative impact on the proper healing of damaged tissue, shifting the regenerative 
curve away from optimal repair and towards fibrosis (Filippin et al., 2011 a & b; Darmani et al., 2004 
a & b). Therefore, NO’s effects on skeletal muscle have been tested in knock-out models as well as 
in disease models (Muscular Dystrophy), however, the concept of using exogenous NO as a 
treatment for acute muscle injury is one that has not been covered in the literature. 
From this evidence, it is necessary to test the potential effects, if any, of an NO-based therapy on the 
regeneration of acutely injured skeletal muscle. Thus, we made use of the NO-donating anti-anginal 
drug Molsidomine, in a rodent model of skeletal muscle crush injury and evaluated whether 
exogenous NO had any effect on muscle repair. Preparation for the undertaking of such a study was 
sufficient, in that Molsidomine is approved for use in humans, and the crush injury model has been 
standardised and repeated by numerous students in our laboratory (Myburgh et al., 2012).  
Before the presentation of the research undertaken, a brief background will be provided on the 
relevant physiological processes (Chapter 2), followed by a more in-depth literature review and 
theoretical framework of the specific topic at hand, NO and skeletal muscle regeneration (Chapter 
3). 
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Chapter 2: Background 
2.1 Normal muscle physiology 
There are approximately 640 skeletal muscles in humans, accounting for a sizable proportion of total 
body mass; just over 30% for most women, and around 38% for men (Scharner & Zammit, 2011; 
Relaix & Zammit, 2012). Skeletal muscles are made up of bundles of long myofibers, which are 
packed with specialised contractile elements called myofibrils; and these contain the sarcomeres that 
are able to generate force through a contraction (see Figure 1.1). Myofibers are formed by the fusion 
of many myoblasts during embryonic and foetal development, and every myofiber is controlled by 
hundreds of myonuclei, giving them a characteristic multinucleated appearance. These myonuclei 
are supplied by the resident muscle stem cells – or satellite cells - during periods of growth, extensive 
hypertrophy or repair, giving skeletal muscle it's robust and unique regenerative capacity (Relaix & 
Zammit, 2012). 
Skeletal muscle allows for the execution of daily tasks, such as eating, whilst additionally, and 
importantly, regulating involuntary actions such as posture, balance, breathing and maintaining an 
optimal body temperature. More complex activities, like playing ice hockey, increase the likelihood 
of damage induced by adverse contraction mechanics or external collision. Muscle also functions as 
protection for bones and organs, which also leaves it vulnerable to external impacts or injuries. This 
concept is the principle focus of this review, as well as of the study reported in this thesis. 
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Figure 2.1 Normal skeletal muscle structure. This figure illustrates skeletal muscle structure, from an entirely 
functional muscle to the proteins within the myofibrils that make up the contractile apparatus. Key structures 
include the basal lamina, under which lie the resident muscle stem cells, or, satellite cells. The many nuclei 
and rich mitochondrial presence are also notable features. Figure taken from Relaix & Zammit, 2012. 
2.2 Muscle injury 
Any muscle of the human musculature may be injured or damaged. Broadly speaking, muscle 
injuries can be classified as contusions, strains, avulsions, exercise-induced injuries or muscle 
disease-related damage. Injuries have a high rate of occurrence, however, treatment strategies 
remain relatively primitive, especially in terms of speeding up recovery, let alone affecting the 
quality of recovered muscle. Research into muscle injuries dates back to times of major war, where 
projectile injuries (Hopkinson, 1963) and other conflict-related injuries were abundant (Saunders & 
Sissons, 1953; Sissons & Hadfield, 1953; Scully & Hughes, 1955). In the following sections, an 
overview of muscle injuries is presented. 
2.2.1 How does injury occur? 
Every day, injuries occur during the normal routine; whether it is a bump on a piece of furniture or 
a fall on the playground. More serious impact injuries occur with moving vehicle collisions or even 
an injury sustained during an earthquake or similar disaster. Thus, injuries may arise from a 
multitude of situations, and with varying degrees of severity, but for the most part, they require 
immediate attention. 
The sporting field is a well-known platform for the occurrence of muscle injuries, and this is not 
limited to contact sports but includes most athletic events and individual sports, such as the hurdles 
or tennis respectively. Moreover, with moderate to severe the injury, one can expect considerable 
time away from activity or competition. In the professional sporting world, this is highly undesirable 
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for both the player and the coach or manager. Athletes are paid to play or compete, thus, when 
injured, they are unable to do what they are paid to do. For example, an elite football team of 25 
players can expect 15 muscle injuries per season, which equates to an average of 223 days of absence, 
including 148 practises and 37 matches missed (Ekstrand et al., 2011). These stats give a rather clear 
indication of the impact that sports injuries have on not only the athletes but also on all stakeholders 
involved. 
A notable example of injury that is not often considered is an injury that occurs in the workplace or 
during work. Whilst this has an obvious effect on the individual's health, work-related injuries have 
an effect extending beyond this narrow concern, in terms of medical and legal expenses, as well as 
expenses from retraining, loss of productivity and an effect on the morale of fellow employees. A 
report from the Australian Bureau of Statistics (2011) stated that in the 2005-06 business year, there 
was an average injury rate of 64 per 1000 people employed, with muscular injuries, including crush 
injuries and strains or sprains, accounting for over one-third of these. It was estimated that this 
equated to 5.9% of Australia’s GDP being spent on work-related injuries; a figure of 57.5 billion 
dollars. 
More examples of injuries include casualties of disasters - both natural and unnatural, casualties of 
wars or civil unrest, trauma resulting with high-velocity projectiles, venom or toxin-associated 
damage, and also injury from immobilisation for extended periods, such as in comatose patients 
after head trauma and drug/alcohol overdose. 
2.2.2 Models of muscle injury 
Since injury can arise from so many different situations, all with varying degrees of severity, the 
study of muscle injury under standardised conditions is a complex undertaking. Furthermore, it is 
not considered ethical to inflict a direct, or traumatic muscle injury to human subjects; for example, 
by experimental contusion injury. Therefore, in our laboratory, models of indirect damage are 
utilised for our human studies, and are known as exercise-induced damage models. These include 
a downhill running protocol (van de Vyver et al., 2015), where subjects run on a treadmill that is set 
on a steep decline, forcing eccentric contractions of the leg muscles for an extended period of time. 
The other model is a plyometric jumping protocol (Macaluso et al., 2012), where subjects complete a 
set number of maximal vertical jumps. While both models elicit significant damage and perceived 
pain in the subjects, the data is relatively incomparable to traumatic impact injuries. 
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In order to conduct good research into direct injury, one has the option of using animal models. 
While these are also heavily regulated by Ethics Committees, they allow for the standardisation of 
various injury models and provide valuable data when employed correctly. Larger animals like 
sheep and rabbits are used, however, rodents – usually rats or mice - are easier to breed, handle and 
house. Furthermore, skeletal muscle proteins and morphology of mammals are highly conserved, 
hence, animal models are appropriate for research. One must keep in mind, however, that these are 
sentient animals, and that research must be conducted with utmost respect and within the stipulated 
guidelines. 
James G. Tidball and colleagues have conducted much research into muscle damage and the ensuing 
inflammatory response in mice in the context of myodystrophy. Their laboratory often utilises a 
model of hind-limb unloading and reloading, where the hind-limb of a rodent is suspended in a 
specialised apparatus for a period of time, after which the limb is released from the apparatus 
allowing for normal ambulation for another period of time (Tidball et al., 1998; Tidball, 2008; Tidball, 
2014). This method allows for the examination of muscle under relatively low-grade contraction-
induced injury, thus providing a strong base or starting point for studies of similar focus. 
Exercise-induced damage, or contraction-induced damage, has more typically been mimicked in 
rats, using stretch-shortening cycle protocols (Baker et al., 2006), eccentric contraction protocols 
(Sakurai et al., 2013) or treadmill running protocols (de Palma et al., 2014). The latter model is also 
valuable for use as a training model (Balon et al., 1997) or for functional testing (Buono et al., 2012; 
Sciorati et al., 2011). Controlled muscle strains are similar to exercise-induced injury, as they are 
usually encountered during exercise activities or on the sports field. This model is usually applied 
by overloading the tibialis anterior muscle of the lower limb of anaesthetized animals (Sakurai et al., 
2005; Ramos et al., 2012; de Paiva Carvalho et al., 2013). 
Another model that may be considered is ischemia-reperfusion injury, a model most utilised in 
cardiovascular research, which is applied by using a tourniquet (often a rubber band) on a target 
muscle group for an extended period of time, and then removing it, allowing reperfusion of the area 
(Lepore et al., 1999; Liu et al., 1998). This model has also been combined in order to compare the 
injury in both cardiac and skeletal muscle tissue (Thiemermann & Bowes, 1997). Overall, however, 
with all of the above-mentioned models considered, the most appropriate model for examining the 
effects of direct trauma appears to be a crush injury model, using the drop mass technique; which 
will be discussed in the following section. 
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2.2.2.1 Specific focus on impact injury 
Mechanical injury results from an impact or a crushing force to the soft tissue and is sometimes 
called a contusion injury, due to the characteristic bruising of the damaged area. Contusions, or 
bruises, account for over 90% of all reported sports-related injuries (Järvinen et al., 2007; Ekstrand et 
al., 2011; Mueller-Wohlfahrt et al., 2013) and tend to plague athletes throughout their entire career. 
The drop mass model, which makes use of a fixed mass free-falling from a fixed height, has been 
utilised in previous research on contusion injuries (Sun et al., 2010; Filippin et al., 2011 a & b; 
Myburgh et al., 2012). Another variation is a controlled crush applied to the musculature with 
forceps (Darmani et al., 2004 a & b); this method is less repeatable, as different researchers may apply 
different amounts of pressure to the forceps. 
Impact injuries do not involve a break in the skin. The mechanical trauma of such an injury causes 
vessel and capillary rupture, infiltrative bleeding, oedema and inflammation, which can all vary 
according to the severity of the injury. If the impact is large enough, there is the possibility of severe 
hematoma formation, which is defined as a mass of blood (usually clotted) that forms in the tissue 
due to ruptured blood vessels; this is especially possible when the large, vulnerable muscle groups 
such as the quadriceps are involved (Ekstrand et al., 2011; Mueller-Wohlfahrt et al., 2013). There is 
also the chance of severely painful compartment syndrome, which occurs when fascial planes limit 
volume expansion, common in the muscles of the lower leg or forearm (Smith et al., 2008). Symptoms 
of contusion injuries, therefore, depend on the internal changes in the skeletal muscle 
microenvironment, but in general, they are characterised by pain in both active and passive motion, 
palpatory pain, visible hematoma, or a combination of these (Järvinen et al., 2007; Smith et al., 2008; 
Ekstrand et al., 2011; Mueller-Wohlfahrt et al., 2013). 
2.2.3 The phases of injury 
After a muscle injury, the muscle tissue undergoes degeneration and inflammation, after which 
regeneration and remodelling occur in an overlapping manner. These events follow a fairly 
consistent phase pattern, which is collectively agreed upon throughout the literature; first is the 
destruction phase, followed by the repair phase and concluding with the remodelling phase. 
Interactions between skeletal muscle and the immune system play a significant role in the course of 
these phases, as will become apparent in the following sections. 
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2.2.3.1 Destruction phase 
This first phase is characterised by the rupture and necrosis of the myofibers, hematoma formation 
between the ruptured myofibers and vast inflammatory cell infiltration; all of which depend on the 
severity of the injury. The injured tissue usually experiences massive vascular damage, depending 
on its degree of vascularization at the time of injury (Sprague & Khalil, 2009; Pugazhenthi et al., 
2008). Thus, not only muscle fibers but also endothelial cells and vascular smooth muscle cells at the 
injury site are damaged. This, combined with the activation of granulocytes and monocytes, results 
in the release of an array of cytokines (initially pro-inflammatory and then anti-inflammatory) and 
the initiation of an inflammatory response (Appleton & Lange, 1994). Cytokines are not the only 
active molecules released at the site of injury. Nitric oxide (NO) also seems to play a role in this acute 
inflammatory response, as the process is significantly reduced when NO production is inhibited by 
L-NAME treatment (Filippin et al., 2011 a & b). The role of NO is a particular focus of this thesis and 
will be discussed in more detail in Chapter 3. 
Neutrophils are the first responding immune cells (granulocytes) infiltrating the injury site during 
this initial phase. Upon injury or infection, chemotactic factors, such as fibrin/collagen or soluble 
factors such as cytokines, are released and these attract circulating neutrophils. The neutrophils 
rapidly adhere to the endothelial lining of the injured site through a process called margination, and 
this is regulated by L/P/E-selectins and adhesion molecules, such as VCAM-1 or ICAM-1 (Appleton 
& Lange, 1994). Neutrophils then migrate through the vessel walls (diapedesis) and infiltrate the 
injured tissue, continuing to accumulate until chemotactic signals stop (for example when the 
cytokine environment changes from a pro- to anti-inflammatory signal). Whilst at the injured site, 
they engulf and destroy any foreign matter or cell debris through non-specific pino-/phago-
/endocytosis. The actions of neutrophils prepare injured muscle tissue for regeneration by removing 
damaged tissue and preparing the extracellular matrix (ECM) for remodelling. The first wave of 
neutrophils usually arrives within 30 minutes of any acute, traumatic injury, with peak neutrophil 
infiltration usually evident at 24 hours post-injury (Smith et al., 2008). After this peak, the numbers 
steadily decline, which is concurrent with an increase in the number of monocytic cells. Whilst the 
neutrophil count does decrease, their numbers remain above baseline levels at the injury site for 
about 5 days, and they remain functionally active during this time (Tidball, 2008). 
After, but overlapping with, neutrophil infiltration we see an increase in macrophage numbers, 
expressing CD68. CD68 is a glycoprotein expressed on the surface of monocytes/macrophages, 
which binds to low density lipoprotein. Along with these macrophages, there is also an elevation of 
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reactive oxygen and nitrogen species (ROS and RNS) (Filippin et al., 2009). Activated macrophages 
are able to secrete multiple products and co-ordinate a large portion of the immune response. They 
engulf foreign particles, which are often larger than the targets of neutrophils (Appleton & Lange, 
1994), and in the case of tissue injury, debris may be of various sizes. Many pro-inflammatory 
cytokines are generated by activated macrophages in the early phase (around 48 hours), namely IL-
2, IL-6 and IL-12, IFN-γ and TNF-α. Upon release, cytokines bind to specific receptors and activate 
signalling pathways giving rise to the expression of proteins playing a role in, for example, adhesion, 
permeability changes and apoptosis. Cytokines may also cause ROS production through 
mitochondrial interactions and may also activate matrix metalloproteinases (MMPs) and integrins, 
which consequently degrade the composition of the ECM (reviewed by Sprague & Khalil, 2009). The 
ECM is made up of a number of structural proteins, such as collagen, and is synthesised by 
fibroblasts, present in the connective tissue. Fibroblasts become activated upon injury and, through 
the signalling from cytokines (for example, TGF-β) synthesise ECM components that are necessary 
for wound healing (Gillies & Lieber, 2012; Lieber & Ward, 2013).  
Finally, an important local cell, the resident muscle stem cells, which are more commonly known as 
satellite cells, are activated by mechanical shear forces from an injury and are influenced by many 
of the other changes in their niche that have been described above. The finer details of satellite cell 
activation are still coming to light, however, the growth factor HGF seems to be one of the key role 
players (Anderson, 2000). Regardless, we do know that once they are activated they begin to 
proliferate rapidly, forming the muscle precursor cells that will eventually repair damaged fibers or 
form completely new fibers, and ultimately restore the damaged area to its former architecture.  
A review by Smith et al., (2008) stated that limiting the inflammatory response in the destruction 
phase may be clinically beneficial in terms of reducing pain and swelling, but that the depletion of 
macrophages may be detrimental to the healing process as it results in reduced satellite cell 
differentiation as well as diminished regeneration and growth of fibers. For this reason, excessive 
use of interventions such as non-steroidal anti-inflammatory drugs (NSAIDs; which inhibit the 
inflammatory response) may promote fibrosis, may delay both early and late phases of regeneration, 
and may ultimately leave the injured area prone to recurrent injuries. A recurring injury to the same 
area can be considered clinically worse than the initial injury (Järvinen et al., 2007). 
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2.2.3.2 Repair phase 
The repair phase overlaps with the latter part of the destruction phase, where any remaining necrotic 
tissue is removed by phagocytosis. This phase is characterised by the emergence of regenerating 
myofibers as well as the production of a connective tissue scar in the damaged area. 
The pro-inflammatory macrophages undergo phenotypic changes that include upregulated 
expression of the CD163 protein. These CD163-positive macrophages are not phagocytic and persist 
within the injured area throughout the repair phase. This response coincides with elevated levels of 
IL-4, IL-10 and IL-13 which are all anti-inflammatory cytokines. The classically activated, CD68-
positive macrophages, have undergone a phenotypical shift that is known as ‘alternative activation’. 
Pro-inflammatory cytokines are reduced and IL-10 seems to be a dominant deactivating cytokine in 
this process as it appears to be intricately involved with the classic to alternate phenotype shift 
(Villalta et al., 2011). The non-phagocytic CD163-positive macrophages are seen to accumulate in 
muscle during regeneration, and it seems that they play an active role in tissue repair; as in vitro 
coculture with rat myoblasts increased proliferation of the myoblasts (Villalta et al., 2011). 
Alternative activation of macrophages also promotes an increased expression of genes involved in 
connective tissue remodelling and adequate fibrosis, essential as the next steps in the recovery of the 
damaged site (Tidball, 2008). Therefore, macrophage phenotypical shift is incredibly important in 
the response to tissue injury as it moves the process forward from the initial destructive phase, which 
would be detrimental if maintained over a longer period.  
By this time in and around the injury site, a large number of satellite cells, positive for the paired 
box transcription factor (Pax7), have been expanding the satellite cell pool. Some of these cells 
expressing the myogenic differentiation factor (MyoD) commit to differentiation into myoblasts. 
Down-regulation of Pax7, maintenance of MyoD expression and the subsequent activation of 
myogenin indicate terminal differentiation (Relaix & Zammit, 2012). After this, they fuse with other 
myoblasts thus replacing the destroyed muscle fibers. Not all of the damaged fibers have necessarily 
been destroyed and the fusion of newly formed myoblasts with these fibers aids in their repair. This 
process is closely associated with the increased synthesis of surrounding ECM and ultimately 
restores the injured area to its previous structure, as effectively as possible. 
2.2.3.3 Remodelling phase 
The final phase also overlaps with its preceding phase and involves maturation of new and 
regenerated fibers, reorganisation of these fibers and finally revascularisation and formation of a 
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functionally repaired whole muscle (Järvinen et al., 2007; Filippin et al., 2011 a & b). Unfortunately, 
the regeneration phase also results in the formation of scar tissue, which is non-contractile tissue 
and must, therefore, be degraded during the remodelling phase. 
As mentioned in the previous section, CD163+ macrophages persist in the tissue and assist with the 
remodelling phase. Transforming growth factor (TGF-β) is a cytokine with a large role in fibrosis 
and scar formation. TGF-β stimulates collagen synthesis and fibroblast proliferation whilst also 
inhibiting differentiation and fusion of myoblasts, all of which promote fibrotic scar formation 
(Leask & Abraham, 2004). This cytokine can stimulate the production of other smaller ECM proteins 
such as fibronectin, and also block their degradation (Brandan & Gutierrez, 2013). Scar tissue is not 
functional skeletal muscle, in that it is unable to contract and it is essentially a way of ‘filling in the 
gaps’ after the destruction caused by the injury. Therefore, the balance between scar formation and 
proper functional regeneration is important in terms of therapies and obtaining optimal recovery of 
the muscle. However, there is an insufficient amount of research on therapies that target fibrosis or 
the remodelling phase specifically, and this will be discussed in more detail in Chapter 2. 
From the above, three main topics can be identified, namely inflammation, muscle regeneration and 
scar formation (fibrosis). Both inflammation and muscle regeneration have been studied extensively. 
Therefore, fibrosis was chosen as the main topic for this thesis. In the next chapter, relevant literature 
in the context of muscle injury and recovery will be discussed. Information on the inflammatory 
immune system is provided in brief for completeness. Satellite cell involvement in muscle recovery 
will be discussed in more detail, as relevant to the thesis topic, while fibrosis and potential 
intervention strategies will be discussed comprehensively. 
2.2.4 Chemical messengers relevant to fibrosis 
2.2.4.1 Cytokines 
Cytokines are small proteins released by many cell types. They may autoregulate and carry signals 
locally between cells, but may also travel in the circulation and exert effects on distant cells. In the 
context of tissue damage, cytokines are mainly produced by immune cells, with the majority 
belonging to the interleukin (IL), interferon (IFN) and tumour necrosis factor (TNF) families. 
Cytokines are key players in the interaction between the immune system and muscle cells 
throughout the repair process (Sprague & Khalil, 2009). 
IL-6 is a pro-inflammatory cytokine released from granulocytes, mainly neutrophils, and from 
monocytes, mainly mature macrophages. IL-6 is also called a myokine, due to the fact that it is 
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released from skeletal muscle in response to muscle contraction during exercise, for example 
(Pedersen & Febbraio, 2008), but also by the injured muscle itself very soon after injury. One of the 
many functions of IL-6 is to signal and regulate the degradation of necrotic tissue after muscle injury 
and enhance lymphocyte proliferation (Smith et al., 2008). IL-10, on the other hand, is an anti-
inflammatory cytokine released primarily from monocytes and has the ability to directly down-
regulate the production of pro-inflammatory cytokines. As mentioned earlier, it plays a major role 
in the macrophage phenotype shift, but it also appears to attract the later invading, alternatively 
activated M2 type macrophages to the injured site, thus promoting an environment of repair and 
regeneration (Villalta et al., 2011). At least one, but probably a combination, of the anti-inflammatory 
cytokines, namely IL-4, IL-10 and IL-13, is responsible for the shift in activation state of macrophages 
from classical (M1) to alternative (M2).  
In addition, expression of IL-4 in muscle is elevated during regeneration, with the myotubes 
themselves acting as the predominant source of the cytokine (Tidball, 2008). IL-4 has a pro-migratory 
function, where emerging myotubes recruit myoblast fusion through the secretion of IL-4 (Horsley 
et al., 2003). IL-4 seems to be required for proper fusion between myoblasts and new myotubes, as 
IL-4 inhibition diminishes migration, which may retard proper muscle regeneration and growth 
(Lafreniere et al., 2006). 
In summary, it is most likely that not one, but all of the aforementioned cytokines are capable of 
inducing alternative activation of macrophages, with the additional possibility of a combined 
expression and signalling effort. 
2.2.4.2 Fibronectin 
Fibronectin is a glycoprotein, secreted predominantly by fibroblasts and chondrocytes, and is a 
major component of the ECM. It functions to enhance the attachment of cells to the ECM through 
the formation of fibronectin-collagen complexes, for example, thus acting as a bridge between the 
cell and its surrounds (Ruoslahti, 1981). Other compounds that fibronectin has an affinity for include 
fibrin, heparin, DNA and actin, and through these interactions, the protein plays a major role in 
wound healing and growth (Carsons, 1989). Fibronectin exists as a high molecular weight (~220kDa) 
protein, however, its integrity may become compromised through alternative splicing or protease 
degradation, where it breaks into multiple fibronectin fragments with varying molecular weights 
from 10 – 200kDa (White & Muro, 2011). MMP-13 and -14 could be responsible for the enzymatic 
formation of fibronectin fragments (Zhang et al., 2012). Fragments seem to retain some functional 
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similarities to the intact protein, for example, in an inflammatory synovial fluid, the fragments in 
the 50 to 100kDa range were able to mediate synoviocyte chemotaxis, and thus may be important in 
establishing chemotactic gradients at inflammatory sites (Carsons, 1989).  
2.2.4.3 Growth factors 
Growth factors are proteins that bind to receptors on the cell surface, resulting in the activation of 
cellular proliferation and/or differentiation and/or growth. Following muscle injury, growth factors 
are important in maintaining the balance between proliferation and differentiation of satellite cells 
as well as the remodelling of newly formed tissue. Below is a brief overview of two growth factors 
that are most relevant to the regulation and repair of muscle injury. 
Hepatocyte growth factor (HGF) has been elucidated as an important and essential factor, especially 
in the acute phase of injury where it is implicated in satellite cell activation (Anderson, 2000; Filippin 
et al., 2009). It is thought that mechanical shear forces mobilise HGF from the ECM. Matrix 
metalloproteinases (MMPs) activate HGF by cleavage. It binds to the c-Met receptor and activates 
the satellite cells, which themselves produce more HGF in an autocrine manner (Anderson, 2000; 
Filippin et al., 2009). To date, HGF is the only known growth factor with the ability to stimulate and 
activate quiescent satellite cells in vivo (Sakuma & Yamaguchi, 2012). 
Transforming growth factor beta (TGF-β) is also released by injured muscle, as well as most 
inflammatory cells, and plays a prevailing role in connective tissue synthesis or scar formation, 
through the synthesis of collagen, fibronectin and proteoglycans (Border & Noble, 1994). It is 
proposed that excessive TGF-β expression leads to fibrosis through fibroblast activation and 
proliferation, which results in sustained collagen and matrix synthesis (Filippin et al., 2009; Rovere-
Querini et al., 2014). TGF-β expression is influenced by many factors in the injured niche. It has been 
shown that inhibiting NO production results in elevated TGF-β levels early on following crush 
injury (Filippin et al., 2011 a & b) whilst additionally causing a chronic overexpression of this growth 
factor (Darmani et al., 2004 a & b), thus promoting fibrosis instead of complete muscle regeneration. 
Fibrosis is of particular interest for this thesis, particularly therapies that target the condition in 
skeletal muscle, as literature on this subject is more limited than that which covers myogenesis. 
Therefore, fibrosis will be discussed in more detail in the following chapter along with the growth 
factors mentioned above.  
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Chapter 3: Literature review 
3.1 Inflammation in response to muscle injury 
Upon trauma, damaged muscle cells initiate the inflammatory response through the release of pro-
inflammatory cytokines. Shortly after this, inflammatory cells populate the damaged area and 
propagate the rest of the response. The interaction between the immune system and skeletal muscle 
is a critical regulatory process, controlling many key events over many days during repair and 
remodelling. Circulating platelets may adhere to the damaged vasculature, becoming activated as a 
result and releasing more pro-inflammatory mediators such as 5-hydroxytryptamine (serotonin), 
histamine and thromboxane A2 (TxA2). Mast cells in the injured tissue may also release histamine, 
which increases the blood flow to the injury site, allowing blood-borne inflammatory cells to gain 
direct access to the injured area (Jancar & Sánchez Crespo, 2005; Sprague & Khalil, 2009). 
The actions of neutrophils – which were discussed in the previous chapter - are a necessary and 
normal response, however, it is a rather ‘messy’ and nonspecific process, causing early, rapid 
removal of necrotic muscle fibers and fiber fragments. Neutrophil invasion is associated with the 
release of high concentrations of free radicals that target the debris for removal by phagocytosis; this 
process is termed ‘the respiratory burst’ and occurs through activation of the enzyme NADPH 
oxidase (Filippin et al., 2009). Proteases are released, which further degrade debris and ECM, whilst 
additional pro-inflammatory cytokines, also triggered by neutrophils, strengthen the inflammatory 
response. In mild skeletal muscle injury, the bulk of the damage to the muscle plasma membrane 
does not result from the primary injury itself, but rather from secondary injury. It is hypothesised 
that superoxide/myeloperoxidase (MPO)-dependent mechanisms, early invading neutrophils and 
the respiratory burst play important roles in this process (Tidball, 2008). Secondary damage is an 
important consideration for any study using an injury model. MPO is an enzyme specific to 
neutrophils and catalyses the production of hypochlorous acid (HClO); a highly oxidative and 
cytolytic free-radical. These neutrophil-derived free-radicals may, through oxidative modification 
of membrane lipoproteins, lead to sufficient membrane damage and prolong the degeneration phase 
(Tidball, 2008). After the neutrophil numbers start to decline, the injured area is invaded by two 
subpopulations of macrophages, which were mentioned in the previous chapter, thus converting 
the damaged area from a pro- to an anti-inflammatory state. It seems then, that a controlled 
neutrophil response, rather than an inhibited one, may be more beneficial in terms of therapeutic 
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strategies. Figure 3.1 depicts the time course of inflammatory cell infiltration into the injured muscle, 
and this time-course is briefly discussed in the next section. 
 
Figure 3.1 Chronological illustration of immune cell involvement after injury. 100% cell presence indicates that 
those cells reached a peak response at that specific time-point after injury. This figure is adapted from a review 
by Smith et al., 2008. 
Recently, Saclier et al., (2013) released a paper, which provides the first in vitro time-course analysis 
of inflammation in a model of muscle regeneration. This model allows for the analysis of each step 
of in vitro myogenesis, including; commitment to myocyte, migration and fusion. At each of these 
steps, macrophages were shown to have essential, orchestrating roles on myogenic precursor cells 
(MPCs), thus illuminating an intricate relationship between inflammatory cells and effective skeletal 
muscle repair; knowledge that until now, was known but not clarified in sufficient detail. According 
to Saclier and her group, macrophages are said to act differentially on MPCs, according to their 
activation state; eliciting trophic effects through the secretion of soluble cytokines and growth 
factors. M1 macrophages migrate toward and stimulate MPC proliferation while preventing 
premature differentiation through the secretion of IL-6, IL1-β, high TNFα and IL-13. Later in the 
time-course of regeneration, M2c and M2a macrophages are known to be present. The in vitro 
experiments showed that, through TGF-β and low TNF-α secretion, M2c and M2a macrophages 
attracted MPCs and stimulated their commitment to myocytes and earlier subsequent formation of 
mature myotubes. 
The latter was a novel finding of this study, where M2c and M2a macrophages decreased MPC 
motility and were better at attracting the MPCs and possibly delivering pro-differentiation cues. 
These particular macrophages also strongly promoted MPC commitment into myocytes - which 
Stellenbosch University  https://scholar.sun.ac.za
- 16 - 
 
precedes fusion - and subsequent formation of large myotubes, as opposed to M1 macrophages, 
which inhibited MPC fusion. IL-4 was proposed as a possible effector for this stimulation of fusion 
by M2c and M2a macrophages. This study is a strong demonstration of the intricate relationship 
between inflammatory signals and the muscle itself, especially after an injury. 
3.2 Muscle regeneration following injury 
Skeletal muscle has an astounding ability to regenerate after any sort of injury. The components of 
skeletal muscle tissue orchestrate its own regeneration through inter- and intracellular signalling 
and repair processes, however, this is a complex process as it combines the actions of multiple 
physiological systems. For the purpose of this review, the following sections will discuss some of 
the skeletal muscle constituents, including satellite cells, that make regeneration possible.  
3.2.1 Muscle cells 
The muscle cell, or myocyte, is a long, cylindrical, multinucleated structure. Whilst the multi-
nucleation is unusual, they share the fundamental properties of most other cells. The bundled 
myofibrils within a muscle cell are bound by a plasma membrane, which is a specialised layer known 
as the sarcolemma; and this is surrounded by an overlying membrane called the basal lamina. 
Between these two membranes lie the satellite cells, and this is discussed in the next section.  
The sarcoplasm is comparable to the cytoplasm of non-muscle cells, however, due to a constant 
energy and frequently high metabolic demand, it contains a very large amount of glycogen, which 
is stored in granular form as glycosomes. It also contains high volumes of myoglobin, the primary 
oxygen-carrying protein within muscle tissue. Importantly, myoglobin may be used as a marker of 
muscle damage, and its presence within the blood is unusual, and may indicate an increase in 
sarcolemma permeability, and thus damage to the muscle fibers (Radak et al., 2012). 
The individual muscle cells are, like the myofibrils they contain, further bundled into fasciculi (see 
Figure 1.1) and grouped accordingly to make up fully functional, whole muscle bundles. The cells 
are provided with structural support by a large complex network known as the ECM, which has 
been mentioned earlier in this review. The ECM is made up of fibrous proteins, such as collagen, 
that are connected by glycosaminoglycans, which are essentially protein-bound polysaccharides 
(Michel et al., 2010). Additionally, the ECM is separated from the sarcolemma of each muscle cell by 
the basal lamina. The ECM also plays a dynamic biochemical role in a variety of cellular functions, 
such as cell survival, cell adhesion, differentiation and proliferation, as well as allowing for cellular 
cooperation in a multicellular environment (Behonick & Werb, 2003). The ECM acts as a store since 
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it sequesters a variety of growth factors, making it possible for very rapid, local, growth-factor-
mediated responses without having to synthesise them from anew. It follows from this then, that 
the formation of the ECM is essential in the process of repair and regeneration, and ECM synthesis 
is actually achieved by the muscle cells themselves, where ECM components are produced 
intracellularly and secreted into the existing ECM via exocytosis (Behonick & Werb, 2003; Engler et 
al., 2006). However, the fibroblasts (myofibroblasts) support this function. 
The ECM and formation thereof is incredibly important to muscle regeneration after an injury. In 
the early phases of injury, after the destruction phase, the ECM functions as a sort of scaffolding 
maintaining the structure of the muscle whilst new fibers are being formed and old fibers are being 
repaired (Lieber & Ward, 2013). Once the muscle tissue is regenerated, remodelling of the muscle 
begins and the ECM is gradually degraded by MMP enzymes (Gillies & Lieber, 2012) until normal 
muscle architecture is achieved. However, in some severe cases of injury, too much ECM remains, 
or not enough is degraded, and what remains is a fibrotic scar which is not beneficial for the overall 
health of the muscle. This scenario of fibrosis will be discussed towards the end of the chapter. 
3.2.2 Satellite cells 
Wedged between the sarcolemma and the basal lamina lies the resident stem cell of skeletal muscle, 
the satellite cell (see Figure 2.1). Satellite cells can differentiate into myoblasts, which can contribute 
to the growth, homeostasis, hypertrophy as well as repair of this tissue. It is because of these cells 
that skeletal muscle displays such great regenerative plasticity, distinguishing it from cardiac 
muscle. Following muscle damage, satellite cells become activated; after which they begin to 
proliferate, differentiate and fuse with other myoblasts, or even with damaged muscle fibers, in 
order to repair muscle fiber ultrastructure. It follows from this that active satellite cells are very 
scarce in healthy muscle, but become proliferative and more abundant upon mechanical stress to 
the musculature, regardless of the severity. A unique characteristic of satellite cells is the ability to 
self-renew and maintain their populations, which fulfils one of the definition criteria of a stem cell 
(see Scharner & Zammit, 2011, for an extensive review). 
Satellite cells do not represent a unique cell type, but rather, a heterogeneous population of muscle 
precursor cells in various stages of activation, proliferation and differentiation. Furthermore, 
although some satellite cell markers, such as Pax-7, CD56 or Ki67, are expressed at various stages 
during injury, the expression patterns differ according to their respective activation state. 
Additionally, not all of the molecular markers are unique to these cells in particular, for example, 
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CD56 is a membrane glycoprotein, also known as a neural cell adhesion molecule (NCAM), and is 
present on a number of other cell types. This makes the selection of satellite cell markers a relatively 
complex process. 
In adult muscle, quiescent satellite cells can be characterised by the expression of paired box 7 (Pax7). 
Conversely, activated satellite cells begin to express CD56 and Myf5, indicating their commitment 
to a muscle progenitor fate. Myogenic Factor 5 (Myf5) is part of the myogenic regulatory factor 
(MRFs) protein family and has a key role in the regulation of myogenesis through its function as a 
transcription factor. Pax7 belongs to a large Pax family of transcription factors. Pax7-null skeletal 
muscle shows a complete absence of satellite cells, and mice with this mutation have a significantly 
reduced body weight (Seale et al., 2000). Moreover, Pax7 induction in foetal muscle stem cells 
promotes satellite cell development specifically, through restriction of alternate developmental 
programmes that these stem cells may follow (Seale et al., 2000). This highlights the notion that 
satellite cells and muscle stem cells are distinctly different cell populations. Furthermore, ablation 
of Pax7-expressing cells renders damaged muscle completely unable to regenerate, with a failure to 
recover this ability (reviewed by Relaix & Zammit, 2012). The progression of satellite cell myogenesis 
is depicted in Figure 3.2 along with the myogenic markers that are expressed at each stage of 
myogenesis. 
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Figure 3.2 Schematic of myogenic progression of satellite cells. This diagram provides an overview of the 
progression of satellite cell fate after activation, and the eventual formation of new myofibers. Also depicted 
are the myogenic markers and their respective expression at each stage of the process. Figure taken from 
Zammit et al., 2006. 
Little is established with regards to how satellite cells remain in a quiescent state, and the exact 
mechanisms behind satellite cell activation also remain elusive. The first factor to be established as 
a satellite cell activator was hepatocyte growth factor (HGF - Allen et al., 1995). HGF is normally 
found in the ECM and is liberated upon mechanical stretch or injury, activating satellite cells 
through co-localisation with the c-met receptor – on the satellite cell surface. More recently in models 
of mechanical shear forces acting on the muscle, it has been shown that NOS enzyme activity is 
required for initial activation of satellite cells (Anderson, 2000), with HGF as another, later stage 
activator (Filippin et al., 2011 a & b; Martins et al., 2011). This information may well lead to 
unravelling the mechanisms behind satellite cell activation. 
What is known regarding activated satellite cells is that MyoD, a transcription factor, is rapidly 
induced in almost all satellite cells at this stage, with these cells then proliferating as Pax7+/MyoD+- 
myoblasts. Subsequently, most of these cells then down-regulate Pax7, but maintain MyoD, thus 
committing to a state of differentiation, through activation of another MRF, myogenin. Some 
remaining cells do the opposite, maintaining Pax7 but down-regulating MyoD, and in doing so, they 
withdraw from the cell cycle and return to myogenic quiescence (Relaix & Zammit, 2012). This co-
expression of Pax7 and MyoD upon activation seems to be a universal feature of all satellite cells 
before the decision to differentiate or self-renew. However, there has been some doubt about the 
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homogeneity of satellite cell characteristics at different stages, due to the differing data reported 
from the various muscle research groups that work in the field. 
Some proliferating satellite cells do not form exactly equivalent cells upon division. In such cases it 
has been observed that one progeny differentiates into a myonucleus whilst the other can remain a 
satellite cell (Relaix & Zammit, 2012); however, understanding is lacking as to which progeny 
undergoes self-renewal and which differentiates, but, Wnt signalling has been implicated (Scharner 
& Zammit, 2011). It was recently suggested that Wnt signalling must be activated for differentiation 
and fusion of myoblasts into myotubes to occur, whereas Notch signalling presides during the 
proliferation of myoblasts (Sakuma & Yamaguchi, 2012). An interesting hypothesis regarding the 
‘plane of cell division’ and daughter cell fate has emerged and is summarised in a review by Bryson-
Richardson & Currie (2008). More specifically, cells dividing along a planar axis, i.e. parallel to the 
basal lamina, give rise to daughter cells with similar Myf5 expression. On the other hand, cells 
undergoing apical-basal division – perpendicular to the basal lamina – give rise to cells with 
differing expression of MRFs. In doing this, satellite cells uphold the maintenance of a pool of 
uncommitted or quiescent cells (MRF negative), which is characteristic of these cells. The roles of the 
ECM and various factors in the niche remains to be explored. 
Unfortunately, skeletal muscle’s regenerative capacity is not without flaws, and a portion of the 
healing is achieved through scar tissue formation (Alessandrino & Balconi, 2013). Therefore, the 
process of myogenesis was not the primary focus of this thesis but rather the events that occur 2-3 
weeks post injury, namely fibrosis. 
3.3 The fibrotic response to muscle injury 
The ECM is a crucial structural component of skeletal muscle with additional roles in muscle 
homeostasis, adaptation as well as in repair; and, there is evidence that the ECM bears most of the 
muscle passive load (see Gillies & Lieber, 2012 for a review). The latter point may indicate that 
perceived stiffness, after exercise or injury, may stem from the ECM itself. Furthermore, nearly all 
pathological changes in muscle, such as those seen in disease states like Duchenne Muscular 
Dystrophy (DMD), result in some form of ECM fibrosis. Importantly, the requirement for ECM 
formation during healing does not allow for therapies that block or inhibit the process. Rather, 
therapies that minimise the scar or speed up the degradation of fibrotic scar tissue during the 
remodelling phase should be used. The next sections will focus on fibrosis, particularly in the context 
of injury to skeletal muscle, as well as the potential of nitric oxide as a therapy for this condition. 
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3.3.1 What is fibrosis? 
Fibrosis is a term used to define the pathological state of excessive connective tissue, or ECM, 
deposition; in response to an injury, this is called scarring. Myofibroblasts – or, activated fibroblasts 
within the muscle tissue - are responsible for the production of connective tissue in skeletal muscle 
fibrosis, and sources of these cells include inflammatory cells, fibroadipogenic progenitor (FAP) cells 
and the resident fibroblasts themselves (see Lieber & Ward, 2013 for a review). The formation of a 
solid connective tissue structure in the damaged area is a part of the normal wound response, and 
after 10 days post-injury this structure begins to disappear due to remodelling, thus leaving only a 
small scar by 21 days post-injury (Järvinen et al., 2005). The muscle’s capacity to regulate 
regeneration and connective tissue formation is compromised, shifting the balance toward excessive 
scar formation and fibrosis.  
The ECM has a strong mechanical influence in muscle function and the effect of fibrosis on proper 
function is both detrimental and clinically relevant. Fibrosis results in decreased fiber size as well as 
increased collagen content, myofibroblast number, inflammatory cell number and myofibrillar 
disorganisation (Lieber & Ward, 2013). The degree of fibrosis varies with the severity of the 
pathological state, for example, DMD, which is characterised by large amounts of connective tissue 
between the fibers; results in the muscle being exposed to a chronic state of fibrosis, which worsens 
with time. However, in the case of an injury, the muscle may only be exposed to a short period (~3-
5 weeks) of fibrosis, where the excess ECM is eventually degraded by matrix remodelling enzymes 
such MMPs, which degrade collagen and fibronectin (Gillies & Lieber, 2012). However, repetitive 
injury as well as factors such as ageing, may offset the balance of remodelling by these enzymes; 
therefore, it is this matrix remodelling phase that is of particular therapeutic interest to this thesis, 
as the concept of speeding up scar degradation, or even producing a smaller scar, is a very attractive 
therapeutic option. 
TGF-β is a prominent cytokine in both initiating and terminating this normal wound repair (Border 
& Noble, 1994) and its actions are summarised in Figure 3.3. However, when the injury is severe or 
when it is a repeated injury, TGF-β production is sustained. TGF-β is a prominent pro-fibrotic 
mediator that is released by inflammatory cells and the damaged muscle itself, and once activated 
TGF-β induces fibroblasts to synthesise ECM components as well as to suppress MMPs (Gillies & 
Lieber, 2012). Collagen and fibronectin are two major constituents of fibrotic connective tissue that 
are synthesised by the TGF-β superfamily, with fibronectin functioning to bind collagen to the 
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muscle cell (Pankov & Yamada, 2002). These two proteins were of particular interest to this thesis, 
and TGF-β is a major target of some anti-fibrotic treatment strategies which will be looked at in the 
next section. 
 
Figure 3.3 The role of TGF-β in normal wound repair. This figure illustrates how TGF-β orchestrates wound healing 
when it is transiently up-regulated. In pathological states this process is overstimulated and excessive matric 
proteins are synthesised. Figure taken from Border & Noble, 1994. 
It is clear from the above that satellite cells play a vital role in maintaining structural homeostasis 
within the muscle tissue, especially after an injury where they are responsible for skeletal muscle’s 
ability to regenerate and repair itself and return to a state of homeostasis. What was also discussed 
was the intricate relationship between satellite cells, muscle cells and the immune system and how 
they combine as a “repair and restore” response upon injury. With regards to therapies for muscle 
injury, targeting the inflammatory response has been a primary focus over the years; with desired 
outcome measures including the reduction of swelling and minimising pain. Given the undesired 
clinical outcomes – such as recurrent muscle tears (Kujala et al., 1997) – linked to excessive fibrosis, 
ideally, a treatment should not only beneficially modulate stem cell and/or inflammatory responses, 
but also this later, more permanent outcome. The following section provides a brief summary of the 
previous, current and prospective therapies for muscle injuries. 
3.4 Therapeutic strategies for muscle injury 
Whatever damage may occur, the action taken often involves one or more strategies, including; 
topical ointments or creams, ingested analgesics (pain-killers) and anti-inflammatories or a trip to 
the doctor, physiotherapist, chiropractor or other health care personnel. Much research and funding 
has, and is still being supplemented into these strategies, however, no solid therapeutic strategy has 
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been universally employed for treatment of soft tissue damage (Järvinen et al., 2007; Mueller-
Wohlfahrt et al., 2013), especially strategies that target fibrosis. 
3.4.1 Traditional strategies 
Treatment principles for muscle damage/injury follow a relatively standardised procedure, and may 
rather be regarded as ‘management’ techniques. The most commonly used acute treatment strategy; 
RICE. This stands for Rest, Ice, Compression and Elevation and is a practical principle, where all 
four methods aim to minimise bleeding into the damaged area and stimulate deep tissue blood flow 
for repair. There are no clinical trials to confirm the effectiveness of the RICE-principle, however, 
there is evidence for the appropriateness of each component (Järvinen et al., 2007). This strategy is 
practically based, allowing for normal healing processes to continue with optimal, but slow, 
recovery of the damaged area. For actual muscle tears, the first step is immobilisation for the first 
few days following the injury, in order to allow the injured tissue to build sufficient strength to 
withstand contractile forces without re-rupturing. Re-rupture injuries are considered the most 
severe type of skeletal muscle injury, causing an excessively long recovery period. 
The common problem with current treatment principles seems to be the rate of recovery from an 
injury, which is ultimately slow; or at least too slow for the casualty and those concerned with 
him/her. This has led to widespread use of NSAIDs, which are some of the most commonly 
prescribed, as well as self-administered, class of drug for any extent of muscle damage/injury (Kim 
et al., 2014). They are usually advised immediately following an injury and are often combined with 
other therapies such as RICE (Järvinen et al., 2007). Still, there is no guarantee of a full recovery, 
where the optimal function is restored in the damaged muscle(s). 
3.4.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
NSAIDs are available as many different classes, differing in terms of strength, inhibitory targets and 
mechanism of action. However, traditional NSAIDs act by inhibiting the cyclooxygenase (COX) 
enzymes, with downstream inhibition of the production of prostaglandins that mediate pain and 
inflammation (Kim et al., 2014). More recently, NSAIDs were altered to selectively inhibit the COX-
2 enzyme, as COX-1 is important to gastrointestinal homeostasis, thus, its inhibition is undesirable 
(Shah et al., 2001). Even with their proven efficacy and suitability for use in humans, they can elicit 
various side-effects such as gastric ulcers (Fine, 2013). Despite this, they remain the most utilised 
type of drug in the treatment of moderate sports injuries (Almekinders, 1999; Rahusen, 2004; Ramos 
et al., 2012). 
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3.4.2.1 Current use of NSAIDs 
In a study by Tscholl et al., (2008), the use of drugs was examined in the 2002 and 2006 FIFA World 
Cups. NSAIDs comprised almost half of all reported medications used, with more than 10% of 
players using NSAIDs before every match. Additionally, this study reported that 86% of 
professional Italian football players were consistently using NSAIDs.  
The sporting field is but one example of the frequency of NSAID use, and given the potential of 
these drugs to interfere with proper muscle healing (Smith et al., 2008) as well as their 
gastrointestinal side-effects (Wallace, 1994), it is necessary to explore more appropriate therapeutic 
alternatives. 
3.4.2.2 History of NSAID use 
The literature on NSAID use dates back to before the 1950’s, where they have since been continually 
prescribed for arthritic conditions. It was around the 90’s when their use came under more rigorous 
scrutiny, due to the high probability of gastrointestinal bleeding from chronic consumption 
(Wallace, 1994) (the pathogenesis of which will be discussed in more detail in section 3.4.2.3 below). 
For this reason, various strategies were employed to develop drugs that would limit these unwanted 
side-effects, for example; the enteric-coating of drugs, the use of prodrugs and selective COX-2 
inhibitors, to name a few.  
3.4.2.3 NSAID mechanisms of GI injury 
In 1998, it was reported that the gastrointestinal (GI) side-effects resulting from NSAID use cause an 
estimated 16 000 deaths and 107 000 hospitalisations each year in the US (Keeble & Moore, 2002). 
These numbers are staggering when one considers that the drugs were being consumed for non-
fatal conditions. From the literature, it is clear that the mechanisms involved in NSAID-induced GI 
injury are multi-factorial, but a general reduction in mucosal defences may be key in the 
pathogenesis of the adverse side effects, clinically characterised by peptic ulcer (gastric and 
duodenal) formation and bleeding. An earlier review by Wallace (1994) highlighted the role of 
prostaglandin suppression in the development of gastric injury, and also reported evidence of 
increased leukocyte (mainly neutrophils) adherence to the vascular epithelium in the gastric 
microcirculation. He suggested that the latter resulted from TNF release in response to NSAIDs, 
leading to a rapid up-regulation of adherence molecules, such as ICAM-1. The resulting neutrophil 
adherence might obstruct the capillaries and reduce mucosal blood flow, as well as be accompanied 
by activation of the neutrophils, with the subsequent respiratory burst causing epithelial and 
endothelial injury and exacerbated inflammation. Wallace also suggested that NSAIDs might 
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combine with bile in the small intestine, created a cytotoxic mixture which further impaired the 
mucosal defences. Following from these key mechanisms, a subsequent review (Rainsford, 2001) 
added that NSAIDs were responsible for the reduction of NO and the increased activity of caspases 
1 & 3 - which facilitate pro-inflammatory cytokine release and apoptosis. Therefore, the addition of 
NO to these NSAID compounds began, with the rationale being that NO would increase gastric 
mucosal blood flow as well as reduce the adherence of neutrophils to the vascular endothelium of 
the gastric microcirculation (Davies et al., 1997). It was subsequently shown that NO-NSAIDs were 
highly effective in reducing gastric side-effects, as well as maintaining their anti-inflammatory and 
analgesic properties (Cuzzolin, 1995; Davies et al., 1997). Wallace and his group were the forerunners 
into NO-NSAID research, with extensive and thorough publications in multiple models, using 
various NO-drug combinations. 
Interestingly, in contrast to the initial effect, NSAIDs were proposed to induce NO at a later phase 
of the same response, when it binds to oxygen radicals to form peroxynitrite, resulting in an NFκB-
mediated inflammatory response. This inhibition and the later induction of NO is most likely due 
to the fact that NO can be synthesised by three different enzymes, which makes it a multi-functional 
molecule involved in many different processes (see section 3.5 for more details on NO). Overall, 
however, NO is probably more beneficial than detrimental in reducing NSAID-induced GI 
ulceration and bleeding, a notion that became apparent in studies that use NO-linked NSAIDs 
(Muscará et al., 1998; Muscará & Wallace, 2006). 
3.4.2.4 NSAIDs and muscle damage 
In an early review of anti-inflammatory treatment of muscle injuries, Almekinders (1999) reported 
that NSAIDs appear to have some beneficial anti-inflammatory effects early in the post-injury 
period, which may transform into an initial clinical improvement. This inflammatory mediation is 
because of the COX inhibition and subsequent decline in prostaglandin production, which was 
already well established by some big names in the field, such as Wallace and Davies (Davies et al., 
1997; Wallace, 1994). Additionally, Almekinders noted that, although NSAIDs have early benefits 
including increased contractile force sooner following injury, they may be associated with unwanted 
effects later on, such as delayed degradation of damaged tissue as well as slowed regenerative 
capacity. It was subsequently concluded that there was no compelling case for aggressive NSAID 
use in the treatment of muscle injuries. A compromise was reached amongst sports medical 
personnel that if NSAIDs were to be used, it should be early in the post-injury period and 
discontinued once the acute inflammatory response has peaked (within ~48 hours) in order to 
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minimise any adverse effects later on in the healing process. Given the lack of consensus and 
insufficient research, the use of NSAIDs is a rather dated approach.  
3.4.3 More recent therapeutic strategies 
From the above sections, it is clear that the treatment of muscle injuries is still very juvenile in its 
methodology, and much is yet to be understood. For this reason, research has branched out to 
explore a multitude of potential therapies and it is even a notion that different therapies that target 
different parameters could be used. 
One strategy is the use of melatonin (Pugazhenthi et al., 2008). Treatment was found to up-regulate 
COX-2 activity and protein levels immediately post-injury. It was also suggested that this increase 
may advance the healing process due to prostaglandin's involvement in fibroblast proliferation and 
promotion of collagen synthesis. Melatonin also accelerated angiogenic processes, through 
increased VEGF expression, and was seen to decrease iNOS activity acutely and then increase its 
activity during the resolving phase – which is similar to the action of NSAIDs. These results 
(Pugazhenthi et al., 2008) however, were reported in a dermal incision wound model; therefore, the 
mechanisms may differ to models of mechanical muscle damage, where the formation of excessive 
collagen may not be desirable. Several other treatments have been tried in other models. 
One study tested the effects of atorvastatin – which reduces LDL and triglycerides, but promotes 
HDL in the blood. It improved the function and morphology of infarcted swine hearts, primarily 
through eNOS activation (Song et al., 2013), which most likely improved cardiac perfusion through 
NO-mediated vasodilation. In a skeletal muscle strain injury model, however, simvastatin seemed 
to increase the extent of damage in terms of gross muscle morphology (Tomazoni et al., 2012). 
In a hindlimb suspension model in aged rats, green tea extract (GTE) – which contains caffeine – 
reduced muscle wasting and atrophy and attenuated the loss in unloading-associated force 
production. GTE also enhanced satellite cell proliferation and differentiation as well as decreased 
oxidative stress (Alway et al., 2014).  
An emerging strategy in the treatment of muscle injury is the use of LLLT or low-level laser therapy. 
LLLT is an infrared (810 nm), a non-pharmacological alternative to commonly used therapies and is 
similar to ultrasound therapy. Lower doses of LLLT, up to about 6 Joules, showed significantly 
improved functional and performance outcomes following a muscle strain injury (Ramos et al., 
2012); whilst the 3 Joule dose improved the rodent walking track index (a functional measure) score. 
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A follow-up study compared the 3 Joule dose, with a traditional NSAID which was applied topically 
in one group and intramuscularly in a second group (de Paiva Carvalho et al., 2013). LLLT reduced 
blood levels of inflammatory prostaglandins more than the two NSAID treatments, and also showed 
a better-improved walking track analysis. 
So, there has been much research into the field of muscle injury, but as of yet, still no ground-
breaking, universally applicable therapy exists. This is probably because therapies should not inhibit 
any natural responses involved in healing. Rather, modulating those processes that have the 
potential to be excessive, such as the inflammatory respiratory burst or the overproduction of ECM 
components that leads to fibrosis should be the goal.  
3.5 Therapeutic strategies that may target fibrosis specifically 
The inhibition of fibrosis is a highly attractive target for improving muscle regeneration and has 
clinical implications for any sort of injury as well as for disease states like the muscular dystrophies. 
This section will cover some of the anti-fibrotic therapeutic strategies that have been researched 
previously, although none have been made clinically available. 
Due to the prevailing role of TGF-β in the fibrotic response, this cytokine is a possible therapeutic 
target. γ-Interferon is a TGF-β pathway inhibitor, and treatment with this cytokine down-regulated 
TGF-β protein expression in vitro, and reduced the area occupied by fibrosis in vivo, in tissue cross-
sections (Foster et al., 2003). The latter result was in a murine laceration-injury model, and the same 
model was used to show that decorin, another TGF-β inhibitor, also improved histological 
parameters of fibrosis as well as function (Fukushima et al., 2006). Whilst these studies show promise 
for cytokine inhibitors as anti-fibrotic therapies in animals, the translation of the results to humans 
is hindered by other quite severe side-effects (Lieber & Ward, 2013). However, losartan is an anti-
hypertensive therapy that blocks angiotensin II receptors and is used in human patients. It is an 
alternative for patients who are intolerant to ACE inhibitors – another blood pressure medication. 
Losartan also seemed to reduce – histologically - the extent of the fibrotic area in lacerated mouse 
muscle (Bedair et al., 2008), but the additional effect of reduced blood pressure must be considered 
here. It seems that an optimal environment is required for efficient repair after an injury, and one 
way to create such an environment may be to maintain proper circulation to the area, especially after 
a crush injury, where vasculature may be damaged. In terms of the latter parameter, a prospective 
candidate for the treatment of injuries may be nitric oxide, which is a potent vasodilator. This 
concept is of particular interest to the proposed thesis and is discussed later in the following section. 
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The aforementioned experimental treatments indicate that fibrosis can be effectively modulated, 
however, there is still a lack of one that is clinically applicable. In addition, similar to the case of the 
traditionally used NSAIDs - discussed in section 3.4.2 - it seems that complete inhibition of pro-
fibrotic signalling pathways is too extreme a strategy, leading to unwanted side-effects and 
ultimately hindering regeneration. The rationale behind the use of NSAIDs was to eliminate an 
inflammatory response, which was successful but did not translate into an overall benefit and had 
some serious side-effects; and the same result is apparent with the use of TGF-β inhibitors. 
Potentially then, a partial modulation is the answer, where normal signalling and responses could 
occur, but to a reduced extent. 
Albeit scarce, evidence has emerged that NO may protect against fibrosis in the tunica albuginea 
and in cardiac and kidney tissue (Ferrini et al., 2002; Kilic et al., 2014). This makes a strong case for 
the investigation of a NO-based therapy for skeletal muscle fibrosis, especially when combined with 
the antioxidant and anti-inflammatory effects (Wallace, 2005; Gupta et al., 2008) as well as the muscle 
repair improvements (Buono et al., 2012) shown by some NO-donating agents such as Molsidomine. 
Knowledge on mechanisms by which NO may interact with fibrotic signals are lacking, however, 
when NO synthesis is inhibited (using nitro-L-arginine methyl ester: L-NAME) the result is an 
excessive expression of TGF-β in the tendons and muscles of crush-injured rats (Darmani et al., 2004 
a & b; Filippin et al., 2011 a & b). So, it seems that NO may play a role in the regulation of TGF-β 
signalling and, therefore, scar formation after injury. Overall, there is a need for the further 
investigation of the effects of an NO-donating therapy in skeletal muscle injury and fibrosis. 
3.5.1 Nitric oxide donors 
The concept of NO-donation as a therapy has been around since the early 1900’s, at least, however, 
there seemed to be some hesitancy before its use; probably due to the notion that too much NO or 
reactive nitrogen species (RNS) may be toxic in some biological environments. Indeed, the presence 
of too much NO/RNS has proved to be detrimental in some cases, including the down-regulation of 
antioxidant systems in skeletal muscle (Lawler & Song, 2002), however, these contraindications are 
primarily experienced under chronic overproduction of NO. The small amount of literature covering 
NO’s role in skeletal muscle does, however, suggest that this molecule is important in all phases of 
injury and repair; whether it be through direct effects or through signalling effects. The potential 
benefits and the potential detriments of NO-donation based therapies in skeletal muscle injury 
require a better understanding of NO, in general. 
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3.5.2 Nitric oxide – what is it? 
NO is a gaseous messenger, best known for its vasodilating and relaxing actions in the vasculature. 
NO is highly reactive, has a very short half-life and can only travel short distances before being 
oxidised. NO determines endothelial function, influences metabolic and vascular health. NO is 
instrumental in coordinating hemodynamic responses and is therefore exploited as a therapy for 
angina, heart failure, pulmonary hypertension and even erectile dysfunction. It is also a potent 
antioxidant, anti-inflammatory agent and antithrombotic factor whilst playing additional signalling 
roles in the nervous and immune systems. Furthermore, in skeletal muscle, NO signalling is 
implicated to have an influence on muscle metabolism, contractility, immune function, cell growth 
and neurotransmission (Dutka et al., 2011). It seems then, that this ‘super-molecule’ is a highly 
attractive therapeutic candidate for a multitude of conditions. 
3.5.3 Sources of NO 
The nitric oxide synthase (NOS) enzyme has three distinct isoforms that are responsible for NO 
production in many different tissues, and these are neuronal, endothelial and inducible NOS (nNOS, 
eNOS and iNOS respectively). Of the three, nNOS and eNOS are constitutively expressed, whereas 
iNOS is induced in response to stimuli, such as inflammation. eNOS is calcium-dependent and 
produces relatively low amounts of NO (Sprague & Khalil 2009). In the context of muscle, its 
expression has also been correlated with mitochondrial content (Kobzik et al., 1995) perhaps due to 
the relationship to capillarization. nNOS is more abundantly expressed in skeletal muscle and 
interestingly, this is mainly in type II fibers, where it is localised to the sarcolemma and interacts 
directly with the dystrophin complex (Kobzik et al., 1995), suggesting mechanical influences. iNOS 
plays an important role in the immune system and is expressed by leukocytes (Sprague & Khalil, 
2009). iNOS is induced by cytokines (Rovere-Querini et al., 2014) and produced in vast quantities 
under inflammatory conditions. NO production through iNOS is thought to be a protective 
adaptation to injury as it reduces leukocyte infiltration and establishes an effective homeostatic 
inflammatory response. This has been confirmed through iNOS null studies (Darmani et al., 2004 a 
& b; Gupta et al., 2008), which reported increased infiltrating neutrophils and the persistence of 
macrophages (Rovere-Querini et al., 2014). 
3.5.4 NO response to muscle injury 
As mentioned earlier, primary muscle injury is combined with an inflammatory response that causes 
NO production at the site of injury in a number of ways. Through calcium-dependent mechanisms, 
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eNOS synthesises a constant, but relatively small amount of NO into the vasculature. However, it 
has been shown that increases in levels of TNF-α – released by injured muscle fibers - decreases the 
translation of eNOS mRNA (Caldwell et al., 2010; Rubinstein et al., 1998), reducing the bioavailability 
of NO (Levine et al., 2012). The primary NOS isoform expressed in skeletal muscle is nNOS, however, 
and quite intriguingly, after an acute injury (by cardiotoxin) nNOS expression was shown to 
disappear, almost entirely, and remain well below normal levels for over two weeks (Rigamonti et 
al., 2013). In contrast, the same research group showed that iNOS, expressed by infiltrating 
macrophages, was significantly elevated after injury in a completely opposite expression pattern to 
nNOS, and was identified as the primary source of NO after acute injury. It was also clear from this 
study that iNOS-derived NO contributed to muscle regeneration, stimulating satellite cell activation 
as well as differentiation. iNOS induction is said to reach a maximum at around 6 hours post-injury 
(Rubinstein et al., 1998; Darmani et al., 2004 a & b; Filippin et al., 2011 a & b), indicating an important 
role for NO in the acute phase of injury. NO’s importance in the acute phase is further promoted by 
the fact that inhibiting NO synthesis with L-NAME resulted in a massive transcription of iNOS 
mRNA (Filippin et al., 2011 a & b), most likely due to lack of autoregulation. 
3.5.5 Opposing results from NO studies 
In very high concentrations, NO-induced apoptosis in skeletal muscle myoblasts that were cultured 
from rat muscles (Stangel et al., 1996). This is relevant in the case of a crush injury, where 
considerable amounts of NO may be present due to the large induction of iNOS shortly after injury 
(Zhang et al., 2011; Filippin et al., 2011 a & b), as well as slightly elevated levels of eNOS (Rubinstein 
et al., 1998). Having said this, there has been some controversy surrounding the study of exogenous 
NO in vitro, as these studies are conducted in the presence of oxygen and may use oxygenated 
buffers, which could react with NO and alter its signalling effects. Nevertheless, it has also been 
proposed high NO may cause serious damage to muscle through excessive vasodilation and 
subsequent ‘hyperperfusion’ of the muscle tissue. Rubenstein et al. (1998), an in vivo study using an 
experimental crush injury in rats, looked at all of the NOS isoforms and found that an induction of 
eNOS was associated with increased capillary perfusion and vasodilation that occurred post-injury. 
This could be a two-sided effect, with the possibility of maintaining tissue viability on the one side 
and the possibility of oedema and hypovolemic shock on the other. Interestingly, before the work of 
Rubenstein and colleagues (1998), it was thought muscle damage occurring from crush injury 
resulted from capillary occlusion and subsequent hypoxia and ischemia of the area. Their data 
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suggests the opposite. This leads to the question of whether or not NO may have any other effects 
that could offset hyperperfusion (if hyperperfusion is indeed a problem). 
3.5.6 Roles of NO that may influence muscle recovery 
NO has been shown to elicit many anti-inflammatory effects (Wallace, 2005). NO decreases 
endothelial cell (EC) activation by leukocytes through reducing the expression of EC-leukocyte 
adhesion molecules, namely VCAM-1, ICAM-1 and MCP-1. A possible mechanism for this may be 
through NO’s indirect inhibition of NFκB, which is a pathway that would otherwise elevate the 
expression of these adhesion molecules. TNF-α – released during inflammation - activates the NFκB 
pathway via ROS; however, NO is able to scavenge, compete with and inactivate ROS, therefore 
reducing NFκB signalling. Importantly, macrophages, endothelial cells and vascular smooth muscle 
cells generate NO at the site of inflammation, thus enabling this inhibition (Sprague & Khalil, 2009).  
Interestingly, a 2011 study by Filippin (also mentioned earlier in the text) found that NO played an 
important role in the normal healing process following acute muscle trauma with a crush injury and 
treatment with L-NAME. Although there was evidence of increased oxidative and nitroxidative 
stress, there was still improved regeneration of the injured fibers without treatment. Therefore, it 
could be that maintenance of blood flow to the injured area is important. Finally, NO decreased scar 
formation following trauma, by decreasing TGF-β expression, therefore lowering collagen 
deposition and shifting away from fibrosis and towards normal regeneration. Furthermore, the use 
of this inhibition model resulted in an acute and a chronic upregulation of TGF-β following an 
experimental crush injury in rats (Darmani et al., 2004 a & b). Thus, the inhibition of NO synthesis 
with L-NAME treatment demonstrates the importance of this molecule (NO) in the balance of 
fibrosis and normal healing.  
Finally, recent work has elucidated some very important functions of NO in the regulation of 
satellite cells in muscle repair. NO was shown to stimulate the proliferation of satellite cells via 
cGMP generation, whilst also maintaining the reserve pool of Pax7+/Myf5- satellite cells through the 
Vangl2-dependent Wnt signalling pathway (Buono et al., 2012). From this it is clear that NO is a key 
messenger in the control of satellite cell number and fate; promoting activation and fusion, and 
ultimately preventing the exhaustion of the reserve pool, all of which are very beneficial to optimal 
healing. 
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Figure 3.4 NO-mediated repair of damaged tissue. NO plays an intricate role in the repair of damaged muscle/tissue, 
predominantly through influences on survival, proliferation and differentiation of satellite cells. The figure 
above summarises a review put forward by Rovere-Querini and colleagues (2014). 
3.5.7 NO-donors and lessons from other models 
In cardiovascular research, much work has been done on NO and NO-donating agents in ischemia-
reperfusion injury models, with some studies including a model of reperfusion of skeletal muscle. 
Reperfusion results in elevations of ROS products as well as NO and its associated products. The 
actions of NO are protective at very small (pico/nanomolar) concentrations, but may become 
cytotoxic at higher concentrations through derivatives such as peroxynitrite (Pacher et al., 2007; 
Liaudet et al., 2009). These radicals are responsible for causing strand breaks in DNA and may cause 
apoptosis through excessive poly (ADP-ribose) synthetase (PARS) activation. PARS is an essential 
DNA repair enzyme, which is beneficial only in moderate amounts. In a model of ischemia-
reperfusion of the hearts or the skeletal muscles of rabbits, Thiemermann (1997) showed that PARS-
dependent cell death of cardiomyocytes did not occur through NO and peroxynitrite, however in 
skeletal muscle myocytes, nNOS inhibition substantially reduced (+/-50%) infarct size, indicating a 
role for NO-mediated cell death - if present in large amounts - most probably through excessive 
PARS activation. This also indicates differential NO signalling in cardiac and skeletal muscle. 
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In other models, where NO-donation and reperfusion injury were studied, NO protected contractile 
function (Chen et al., 1998), whilst additionally attenuating mitochondrial swelling and 
degeneration. S-nitroso-acetylcysteine (SNAC), an NO donor, was also shown to maintain 
microvascular perfusion. NO donors, therefore are able to reach the tissues, cells and organelles. 
Infusion of L-arginine increased NO production and inhibited superoxide production, showing that 
L-arginine may enhance eNOS activity (Balon et al., 1997). 
To examine what happens when NO is not present, L-NAME is often used to inhibit the activity of 
the NOS enzymes. In particular, iNOS inhibition has been shown to result in an extraordinarily large 
adherence of inflammatory cells to damaged tendon and muscle, three days following a crush injury 
to the digital flexor tendon (Darmani et al., 2004 a & b). This was also associated with an imbalance 
between NO and TGF-β, indicating then, and this has been subsequently proposed (Filippin et al., 
2011 a & b), that NO is essential for a normal inflammatory response. 
3.5.8 Limitations of in vitro studies investigating NO Donors 
We have identified an NO donor, Molsidomine, to use in this context of our injury model. 
Molsidomine is an NO-donating anti-anginal drug that is approved for use in human patients. This 
drug is ingested and metabolised in the liver to liberate SIN-1, which then dissociates spontaneously 
in aqueous environments to liberate NO (Kilic et al., 2014). Many research groups have used 
Molsidomine and it has effects other than vasodilation, such as non-hepatic glucose uptake in 
hyperglycemic and hyperinsulinemic conditions in fasted dogs (An et al., 2008). The afore-
mentioned study made use of SIN-1 as an NO donor, but it is also used in some cases as a 
peroxynitrite donor (Kanazawa et al., 2000; Hemanth Kumar et al., 2013), which may seem confusing 
until explained by the chemistry behind it. 
In an oxygenated buffer, SIN-1 dissociates into both superoxide and NO, and these spontaneously 
form peroxynitrite (OONO-) (Huie & Padmaja, 1993). The reaction between NO and superoxide is 
an extremely fast reaction, therefore, NO is scavenged rapidly, and, in such a situation, would be 
unable to exert any beneficial effects as a lone-standing molecule. Without the presence of 
superoxide, NO might not be scavenged so rapidly, and may be ‘allowed’ to exert vasodilating and 
anti-inflammatory effects. However, in vivo, or in the presence of biological electron acceptors (e.g. 
heme proteins like myoglobin), SIN-1 acts as an NO donor rather than a peroxynitrite donor (Singh 
et al., 1999). In other words, when oxidising agents other than molecular oxygen are present, which 
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is true for in vivo conditions, these agents may compete with oxygen to oxidise SIN-1 and form NO 
without concomitant superoxide production (see Figure 3.5).  
 
Figure 3.5 The oxidisation of SIN-1. The asterisk (*) indicates where oxidising agents (e.g. myoglobin) may compete 
with molecular O2 and form the SIN-1 • + cation radical and NO without forming superoxide (O2 • -). Diagram 
taken from Singh et al., 1999. 
In a biological system (organism), it is most likely that SIN-1 generates both peroxynitrite and NO, 
with the ratio depending on the oxygen concentration as well as the concentration of endogenous 
oxidants. Beneficial effects of SIN-1 in reperfusion injury studies (Yeh et al., 2004) suggest that NO 
mediates the attenuation of such an injury by scavenging oxygen. However, peroxynitrite has been 
shown to exacerbate reperfusion injury and it is thus unlikely that SIN-1 produced large amounts of 
this product. Subsequently, it is advised that the use of SIN-1 as either an NO donor or a 
peroxynitrite donor cannot be determined by the chemical interactions of SIN-1 are fully understood 
in the system being studied (Singh et al., 1999). Additionally, a review of the literature by Liaudet et 
al., (2009) elucidated a dysregulatory role for peroxynitrite in a multitude of signalling pathways; 
ultimately triggering the development of cardiovascular pathologies through excessive tissue 
damage. However, the review emphasised that these effects had only been confirmed in in vitro 
studies.  
Due to the above-mentioned discrepancies, we chose to evaluate SIN-1 (in the drug form of 
Molsidomine) in an in vivo model of skeletal muscle injury and regeneration. Molsidomine is taken 
orally and must be enzymatically cleaved in the liver to release the active metabolite, SIN-1. In this 
way, our study is not compromised by any oxygenated buffers or atmospheric interactions and 
ultimately provides a robust evaluation of the actions of this drug in vivo.  
* 
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3.6 Hypothesis 
After a thorough review of the available literature as discussed above, I have formulated the 
following research question:  
 Does exogenous NO improve tissue recovery in acutely injured muscle, compared to 
placebo-matched controls?  
My hypothesis was that acute post-injury NO supplementation by in vivo treatment with an NO-
donor will modulate inflammation, improve myogenesis and reduce the degree of fibrosis after a 
muscle-damaging crush injury to the gastrocnemius muscle of rats. 
In order to test this hypothesis, I have formulated the following objectives: 
 To induce an experimental crush injury in rats. 
 To assess the effect of acute Molsodomine treatment (NO-donation) on the following: 
o Extent of inflammation, as assessed by MPO protein levels in injured muscle tissue 
o Effect on processes of reparative satellite cell proliferation and differentiation 
o Effect on the degree of fibrosis, as indicator of the quality of tissue repair 
o Potential mechanisms involved in fibroblast deposition 
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Chapter 4: Research Methods 
4.1 Ethical considerations  
All experimental procedures were approved by the Animal Research Ethics Committee of Sub-
Committee B of Stellenbosch University’s Research Development Division (Ref. #: SU-ACUM14-
00008). Care was taken to minimise the number of animals used while allowing for sufficient 
statistical power. All experiments on animals were carried out in accordance with the guidelines of 
the Medical Research Council. 
4.2 Experimental animals 
For this study, young-adult (2½ – 3 months), male Wistar rats (n = 58) – species Rattus Norvegicus - 
weighing between 320g and 420g were used. Rats had access to standard rat chow (Imbani Nutrition, 
Western Cape, South Africa) – for which nutritional information is presented in Table 4.1 – and tap 
water ad libitum while being exposed to a 12hr light/dark cycle (lights on at 6:30 a.m.). The 
temperature in the housing facility was controlled at 21°C and ventilated at 10 air changes per hour. 
Table 4.1 Nutritional information of rodent chow. 
Protein Moisture Lipids Fibre Phosphorus Calcium 
160 g/kg 120 g/kg 25 g/kg 60 g/kg 7 g/kg 18 g/kg 
Rat Chow Ingredients (Imbani Nutrition) 
 
 
The arrival of animals at the department’s small laboratory animal facility and entry into the study 
protocol was staggered, due to limited capacity in the facility. On arrival, animals were kept in large 
cages in groups of six for approximately one week, after which they were randomly assigned to 
smaller cages, in groups of three for the remainder of their intended study period. For enrichment, 
a small section of PVC piping was placed in the cage, through which the animals could walk and in 
which they could sleep. Rats are naturally communal animals, thus, they were not housed 
individually. 
Table 4.2 Average rat weights (g) between post-injury time points. 
Day 1 (n=22) Day 3 (n=12) Day 5 (n=12) Day 21 (n=12) 
352,09 (± 20,65) 356,75 (± 15,36) 363,83 (± 26,53) 372,79 (± 28,53) 
Average Weight (± SD) 
 
 
Stellenbosch University  https://scholar.sun.ac.za
- 37 - 
 
Once in their appropriate cages, experimental animals were randomly divided into their respective 
experimental groups (total number of animals = 58). 10 animals were used as uninjured controls 
receiving either Placebo treatment or Molsidomine treatment (n = 5 per group). The remaining 48 
animals were also randomly divided into Placebo or Molsidomine treatment groups and were 
euthanized at four post-injury time-points (n = 6 per time-point per treatment group). The rats were 
further divided into four groups of six rats for each time point. The researcher was not blinded to 
the cage allocations. The time-points for sample collection were 1 day, 3 days, 5 days and 21 days 
post-injury. (At the time that this protocol was planned, it was not common practice to use control 
groups for every time-point examined, therefore, we opted for the use of fewer animals). Average 
body mass measured at different time points are provided in Table 4.2, and a breakdown of the 
experimental animal groups is depicted in Figure 4.1. 
 
Figure 4.1 Experimental animal grouping. The figure above illustrates how the experimental animals were divided 
into the necessary study groups. A total of 58 animals were used for the study. 
 
4.3 Drug intervention 
As mentioned already, since the aim of the study was to investigate the role of NO in muscle 
regeneration following a crush injury (discussed in the following section), an NO-donating, anti-
anginal drug that delivers the molecule into the circulation – Molsidomine – was chosen as 
intervention drug. Molsidomine (Cat. #: M2901, Sigma-Aldrich, USA) is a pro-drug for the formation 
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of NO (see Figure 4.2). Upon ingestion, it is rapidly absorbed and hydrolyzed in the liver into the 
active metabolite 3-Morpholinosydnonimine, or SIN-1. SIN-1 has a half-life of 1 to 2 hours, however, 
the total duration of therapeutic action seems to be longer than expected (See Rosenkranz et al., 1996, 
for pharmacokinetics of Molsidomine). Administration of Molsidomine was by oral consumption of 
jelly blocks, at a dose of 3mg/rat. Each block was individually prepared by dissolving the drug in 
pre-set jelly (1 block = 1 dose). In our opinion, this route of administration was less stressful to 
experimental animals in comparison to e.g. oral gavage. For dosage, a paper by Singh et al. (1999) 
found that there was no difference in effects obtained for doses from 0.1mg, up to and including a 
dose of 1mg in vitro, thus, we chose a dose relevant to a clinical situation, and similar to other studies 
in rodents (Öztürk et al., 2009; Zordan et al., 2013). 
Commercially available dessert jelly (Moirs) was purchased and prepared as per supplier 
instructions. An extra tablespoon of gelatine (Moirs) was added to the mixture, so as to provide extra 
structure to each block. Jelly blocks were prepared in an ice tray (~2mL each). A 3mg dose of 
Molsidomine was dissolved in 500µL of dH2O and mixed into each block. The tray was then placed 
back in the fridge (4°C) and left overnight to cool and to be used post-injury and one day after the 
injury. Thus, Molsidomine-infused jelly blocks were kept for a maximum of two days. 
 
Figure 4.2 The formation of NO from Molsidomine in vivo. This figure shows the progressive metabolism of 
Molsidomine once it is ingested. The drug is broken down by the liver into SIN-1 which enters the circulation 
and liberates nitric oxide. Adapted from Rosenkranz et al., 1996. 
 
4.4 Injury intervention 
The crush injury, or drop mass model, has been utilised extensively in our department, in order to 
study muscle damage (e.g. Myburgh et al., 2012), and was chosen as it effectively elicits a 
reproducible and quantifiable injury. The model involves dropping a fixed mass onto the desired 
muscle group of the animal from a fixed height. In this study, a 250g, flat-bottomed, cylindrical 
weight was dropped onto the medial surface of the right gastrocnemius muscle of each rat, from a 
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height of 50cm. This procedure induces a contusion in a non-invasive manner, with no bone 
involvement. Figure 4.4 clearly depicts the apparatus used for this procedure. 
 
Figure 4.3 Apparatus utilised for anaesthesia. (A) Ohmeda Isotec 4 Isoflurane Vaporiser 
(OMED of Nevada, USA). (B) Rat under anaesthesia with gas mask. Note the shaved 
right leg. 
Animals were anaesthetised before the injury intervention with 3% isoflurane gas in oxygen and 
anaesthesia was maintained throughout the injury process with a funnel fill isoflurane vaporiser 
(Ohmeda Isotec 4, OMED of Nevada, USA; Figure 4.3 A). Our apparatus is set up with a falcon tube 
at the end of the gas tube, which acts as the face-mask for the animal (Figure 4.3 B). The animal’s 
lower leg was then shaved using a battery-powered razor (Sassoon Appliances, Model VSTR8161), 
in order to view the site more clearly (see Figure 4.3 B). Animals were positioned on their back, in a 
supine position, and their right lower leg was placed on the crush-platform. The drop-weight was 
then rested, lightly, on the desired injury site to ensure correct placement of the limb. We aimed to 
target the medial portion of the gastrocnemius muscle group. In order to standardise the procedure, 
a length of approximately 1.5cm above the heel was chosen as the site for delivery of injury. The 
animal’s leg was supported in place by the researcher, using the index finger to keep the knee in 
place while the thumb and middle finger held the animal’s foot for support (all with the left hand). 
Once ready, the researcher lifted the weight up by means of a string attached to the weight, and then 
secured the weight in place (at 50cm) with a pin (all with the right hand, maintaining the left hand’s 
supporting position). The pin was then pulled out, allowing the weight to fall freely down the tube 
and onto the animal’s leg, for only one repetition. Animals were then placed into individual cages 
until fully recovered. This exact procedure was used for each animal of the injury groups. 
A B 
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Figure 4.4 Apparatus utilised for the crush-injury intervention. Depicted above; (A) the full length of the drop tube 
together with anaesthesia set-up, (B) a closer view of the crush-platform and weight, (C) the 250g weight and 
(D) the removable trigger pin set at a 50cm height. 
4.5 Sample collection 
All animals were placed under general anaesthesia by inhalation of 3% isoflurane gas (ISOFOR, Safe 
Line Pharmaceuticals (Pty) Ltd., South Africa) in oxygen, prior to sample collection, and 
reactions/reflexes were tested with a toe pinch. Anaesthesia was maintained at 3% until the animal 
was non-responsive, which was approximately 10 minutes. Blood collection occurred first, after 
which the animal was humanely euthanised by removal of the heart, and the gastrocnemius muscles 
from both legs were then swiftly extracted. A summary of the protocol is presented in Figure 4.5. 
 
Figure 4.5 Study design for injury, treatment and sample collection. Either Placebo or Molsidomine treatment 
occurred immediately and 24 hours post-injury and study groups were euthanized at 1, 3, 5 and 21 days after 
injury. The number of animals used for each experimental time-point is indicated on each rodent illustration. 
4.5.1 Muscle 
The gastrocnemius muscles from both left and right legs of each animal were collected (although 
only muscle on right leg was exposed to contusion) and snap-frozen in a cryoprotectant for later 
analysis. To do this, the skin of the lower leg was removed to expose the lower-leg muscles. Using a 
scalpel, the fascia was removed along with the surrounding tissue, until the gastrocnemius was 
clearly visible. The scalpel was then placed behind the Achilles’ tendon and drawn along the tibia 
with the blunt edge facing forward, freeing the tissue from the bone and allowing for easy extraction 
A B C D 
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of the entire muscle. The sample was then excised, cut into two pieces each of which was snap-frozen 
and stored at -80°C. The injury site was clearly visible in the injured animals (see Figure 4.6), and 
the injured site was separated into two halves to allow for more rapid freezing throughout the tissue 
(see Figure 4.7 for an illustration of excision details). For snap-freezing, 2-Methylbutane (or 
Isopentane – Cat. #: 277258, Sigma-Aldrich, USA) was placed into an aluminium can, which was 
rested in a polystyrene container, filled with liquid nitrogen. Once the Isopentane had just begun to 
freeze (determined by white solidification of Isopentane around the sides of the container), the 
excised section of muscle was submerged in it for approximately 20 seconds before being placed in 
a 5mL stand-alone reaction vial for storage at -80°C. Holes were punched in the lids of the tubes to 
eliminate pressure build up. 
 
Figure 4.6 Depiction of the injury zone after injury intervention. Here we compare an uninjured animal (A) to an 
injured animal (lateral view in (B) & medial view in (C)) 24 hours after the crush injury. A contusion is clearly 
visible in the injured area in (B) & (C). The site of injury is indicated by a white arrow. 
4.6 Sample analysis 
4.6.1 Determination of NO metabolites in injured tissue 
Tissue lysates were prepared according to Appendix III. Lysates were spun for 30 minutes at 14 
000g, through a filter with a nominal molecular weight limit of 3kDa (Merck KGaA, Amicon Ultra-
0.5mL Centrifugal Filter Unit, Cat. #: UFC500324, Germany), in order to remove proteins; which may 
otherwise give falsely elevated levels of NO metabolites, or NO.  
Subsequently, levels of nitrite and nitrate were determined, as indicators of the presence of NO, 
using a colorimetric Nitrate/Nitrite assay kit (Cat. #: 23479, Sigma-Aldrich, USA). The kit detects 
total NO metabolites using the Griess reaction (Granger, 1996), which involves azo coupling 
between diazonium species. The absorbance of the azo compound was measured 
spectrophotometrically at a wavelength of 540nm using a Microplate Spectrophotometer 
(Powerwave HT, BioTek Instruments, Inc., VT, USA), running Gen 5 Data Analysis Software. Values 
A B C 
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were extrapolated from nitrite/nitrate standard curves that were prepared according to the 
manufacturer’s instructions. The detection limit of the assay was 10μM, or 0.46 ng/μL for nitrite and 
0.62 ng/μL for nitrate. 
4.6.2 Histological analysis of muscle morphology 
4.6.2.1 Hematoxylin & Eosin staining 
In order to view the overall muscle structure, we made use of an H&E stain. Hematoxylin 
(basic/positive) binds to and stains all DNA/RNA (acidic/negative) structures purple/blue. Eosin 
(acidic/negative) counterstains all proteins of the tissue (basic/positive) to shades of pink; examples 
of proteins include cytoplasmic filaments, intracellular membranes and extracellular fibers (Bancroft 
& Cook, 1994). 
Cross-sectional, 10μm cryosections were prepared with a cryostat (Leica CM1860 UV, Leica 
Biosystems Nussloch GmbH, Germany) at -25°C. For each piece of injured muscle tissue, 
approximately 1cm of tissue was cut away from the distal end of the sample. This was an attempt to 
standardise the sectioning procedure, and it was agreed that the injury zone was most distinct at 
this particular area of each sample. The sample preparation procedure is depicted in Figure 4.7. 
About 4 to 6 muscle sections per sample were placed on an uncoated microscope slide and allowed 
to air-dry at room temperature for approximately one hour. Slides were either stained after the one 
hour of drying, or they were stored at -20℃ for later staining. In the case of the latter, slides were 
allowed to thaw at room temperature for 5 minutes before staining.  
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Figure 4.7 Depiction of sample handling, excision and positioning for cryosectioning. Each injured muscle sample 
was handled in the manner illustrated above. The injury was induced to the same area of the gastrocnemius 
muscle for each animal, which was approximately 1cm from the distal end of the muscle. Uninjured muscle 
samples were prepared in exactly the same way. 
The H & E staining procedure was done using an automatic slide staining apparatus (Leica ST4020, 
Leica Biosystems Nussloch GmbH, Germany – see Figure 4.8). The slides were submerged in freshly 
prepared reagents for two minutes per reagent, in the following progression: tap water, two changes 
in Mayer’s haematoxylin, warm tap water (26°C), Scott’s tap water, tap water, Eosin (5% in 95% 
Ethanol), tap water, 95% Ethanol, 100% Ethanol and finally, clearance in xylene. Once stained, the 
slides were mounted with DPX mountant (Cat. #: 06522, Sigma-Aldrich, USA) and covered with a 
cover-slip for viewing. See Appendix I for a detailed protocol. 
Slides were viewed in bright-field on a microscope (Nikon ECLIPSE E400), mounted with a camera 
(Nikon DS-Fi2), and processed through a Nikon Digital Sight DS-U3 processor (Nikon, Japan). 
Image processing was done on NIS elements v4.10, on a Dell desktop computer (Dell, USA) running 
Windows 7 (Microsoft, USA). 
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Figure 4.8 Automatic slide staining apparatus. The above apparatus (Leica ST4020, Leica Biosystems Nussloch 
GmbH, Germany) was utilised for H & E staining procedures. 
4.6.2.2 Trichrome staining for connective tissue 
The trichrome stain is a broad term used for a stain comprising three colour components, one of 
which is a nuclear stain. For this particular study, a Masson’s trichrome stain was employed for the 
histological visualisation of collagenous connective tissue fibers in frozen tissue sections of rodent 
gastrocnemius muscle cross-sections. In brief, collagen is stained blue, muscle fibers are stained red 
and nuclei are stained black/purple. 
For this stain, 10μm cross-sections of injured muscle were again prepared. Prior to sectioning, 
microscope slides (Lasec, South Africa) were coated with 0.1% (w/v) Poly-L-Lysine (Sigma-Aldrich, 
Cat. #: P8920, USA) in H2O and allowed to dry. About 4 to 6 muscle sections were placed on each 
microscope slide and the slides immediately frozen and stored at -20°C for later analysis. 
The stain was carried out according to Appendix II, and the collagen stained area was quantified. 
4.6.2.3 Image analysis of Masson’s trichrome stain 
Stained slides were viewed in brightfield as previously described in section 4.6.2.1. Using the NIS 
software, images of the tissue were captured at 4x magnification and stitched together (with the 
stitching tool) to create an image of the entire piece of tissue (see Figure 5.6 A-C). Because rat muscle 
is relatively large, the muscle fibers and the blue-stained collagen were easily visible at this 
magnification. 
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Once images were acquired, they were analysed using Image J software (Schneider et al., 2012). 
Briefly, the background was subtracted and brightened to make each colour stand out. The image 
was converted to a red/green/blue (RGB) stack and the analysis measurements set, namely ‘area’, 
‘area fraction’, ‘limit to threshold’ and ‘display label’. The threshold was then adjusted to optimise 
the red and blue filters and then measured, with the result being the area of blue colour as a 
percentage of the area of the entire piece of tissue. Entire muscle sections from six animals were 
analysed in this way for both the Molsidomine and the placebo groups, and four uninjured and 
untreated animals were used as controls. 
4.6.3 Analysis of tissue lysate protein expression 
4.6.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Tissue lysates were prepared and an SDS-PAGE carried out according to the protocol in Appendix 
III. Briefly, hand-cast polyacrylamide gels were run in a standard bench-top electrophoresis unit 
(Bio-Rad Mini-PROTEAN® Tetra Cell, USA), and consisted of a 4% stacking gel and either an 8% or 
a 12% separating gel, depending on the target protein. Prior to sample loading, tissue lysates were 
mixed with 5μL of Laemmli solution and boiled for 5 minutes at 95°C. A Precision Plus Protein™ 
Kaleidoscope™ marker (Bio-Rad, Cat. #: 161-0375, USA) was used obtain protein band sizes. Gels 
were run at 70V for approximately 3 hours. Each gel compared samples from the injured legs (right 
legs) of the Placebo (CX) and the Molsidomine (MX) groups, n = 6 for each group per time point. 
Also, present in each gel was a reference sample, which was tissue homogenised from a single 
animal that had not been treated or injured. Once run, the gels were prepared for Western blotting. 
4.6.3.2 Western blotting 
Western blot analysis was carried out according to the protocol in Appendix III. SDS-PAGE proteins 
were transferred onto a nitrocellulose membrane (GE Healthcare, Life science, RPN 3032D, UK) via 
a transfer system (Turbo-blot, Bio-Rad, USA). Blots were transferred at 25V and 2.5A for 20 minutes, 
and the successful transfer was confirmed by Ponceau S. staining. Membranes were then blocked 
with 5% fat-free milk (Parmalat SA (Pty) Ltd., South Africa) for one hour at room temperature, and 
treated with primary and then horse-radish peroxidase (HRP)-linked secondary antibodies, which 
are presented, along with their dilutions, in Appendix IV. After secondary antibody incubation, 
membranes were washed 4 x 5 minutes with 1% Tris-buffered saline in Tween® 20 (TBS-T), followed 
by addition of enhanced chemiluminescence substrate (SuperSignal® West Femto Maximum 
Sensitivity Substrate, Cat. #: 34095, Thermo Scientific, USA). Membranes were subsequently imaged 
using the Chemidoc MP (Bio-Rad, USA) that was supported by Image lab software 4.0 (Bio-Rad, 
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USA). Immunoreactive proteins were normalised against the Ponceau S. staining and further 
normalised with the uninjured reference sample, which allowed for the comparison of protein 
expression of all samples, irrespective on the particular gel they were analysed on. 
4.7 Statistical analyses 
All data are represented as means ± standard deviation of the means (SDs). Student’s t-tests were 
performed for comparisons between simple sets of parametric data and paired Mann-Whitney U 
test for non-parametric data. Additionally, two-way ANOVA was performed to compare effects of 
treatment and time on the two groups, with Fischer-LSD posthoc tests being performed where 
appropriate. (Since different rats were used for different time points, repeated-measures ANOVA 
was not appropriate.) All statistical tests were performed in consultation with an experienced 
biostatistician (Prof Martin Kidd, Stellenbosch Statistical Consultation Centre, Stellenbosch 
University, South Africa) using Statistica (13th edition, StatSoft, Sandton, South Africa), and all 
graphs were prepared using Prism 5 (GraphPad Software, Inc., USA). A p-value of less than 0.05 
was accepted as statistically significant. 
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Chapter 5: Results 
5.1 Validation of nitric oxide delivery by Molsidomine 
In order to confirm that Molsidomine caused an increase in nitric oxide, nitric oxide’s metabolites 
were measured in filtered tissue homogenates one day after injury in all four experimental groups. 
At this time point, all animals would have received two doses of either Placebo- or Molsidomine-
infused jelly blocks. 
Unfortunately, NO metabolite (nitrate and nitrite) values for all samples were below the detection 
limit of the kit used. Therefore, we can make no conclusion from the data and it will be omitted from 
the discussion.  
In future, it would be important to include a positive control for this assay, such as E.coli (positive 
for nitrate reduction) and A.baumannii (negative), that that we may validate whether there was a 
problem with the assay, since at the moment, there is no literature with information on the expected 
normal levels of these parameters in skeletal muscle tissue. 
5.2 Tissue morphology following a crush injury 
Injured tissue was qualitatively evaluated at all time-points in Placebo and Molsidomine groups by 
H&E staining. Figures 5.1 and 5.2 depict a timeline of injury-regeneration progression from 1 day to 
21 days after an acute crush injury. Time course seemed similar for both Placebo and Molsidomine 
treated groups when visualised at a low (4x) magnification. At a higher magnification (40x), the 
damaged fibers are visible at 1 day, and these are characterised by poorer uptake of the eosin dye 
(see black arrows in Figure 5.2 B and C). By the 3-day time point, much of the debris is cleared away, 
but in the Placebo group, the fibers are still undergoing necrosis. Inflammatory cells are still 
abundant at day 5, but it is possible to see a reorganisation of the tissue and a clear area of 
regeneration, with small, lightly stained new fibers. Three weeks after the injury, the injury site is 
still visible, with newly formed fibers arranged into bundles.  
Despite the similar time course for recovery, some distinct differences were observed in the 
qualitative comparison of Placebo and Molsidomine groups. Firstly, the magnitude of inflammatory 
infiltrates (5 days) seemed to cover a smaller area in the Molsidomine treated group, with larger 
fibers on the border zone. Secondly, better reorganisation and regeneration at the site of injury was 
evident 5 days after Molsidomine treatment. Additionally, at 21 days, centrally nucleated 
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regenerating fibers were larger and arranged closer together in the Molsidomine treated group. 
These observations are in accordance with other findings presented in the following sections. 
 
Figure 5.1 H&E stained images at 4x magnification. (A) Control uninjured sample with normal muscle architecture. 
(B, D, F, H) Injured and Placebo-treated muscle tissue. (C, E, G, I) Injured and Molsidomine treated muscle tissue. 
Black arrows indicate inflammatory infiltrate. Black asterisks indicate newly regenerated muscle tissue in the 
injury zone. Scale bar represents 200µm. 
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Figure 5.2 H&E stained images at 40x magnification. (A) Control uninjured sample with normal muscle architecture. 
(B, D, F, H) Injured and Placebo-treated muscle tissue. (C, E, G, I) Injured and Molsidomine treated muscle 
tissue. The figure key provides an explanation of the image annotations. Scale bar represents 50µm. 
5.3 Post-injury MPO release 
Western blots analysis of MPO content in gastrocnemius muscle homogenates revealed a main effect 
of time (ANOVA p < 0.0001), where MPO protein content was significantly elevated on day 5 post-
injury, irrespective of treatment.  Although no treatment effect was observed statistically, the peak 
in MPO content 5 days after injury was approximately 33% lower in Molsidomine treated animals 
(Figure 5.3). 
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Figure 5.3 Western blot quantification of total MPO content as an indicator of inflammation in crush-injured rat 
gastrocnemius muscle. (A) Densitometry was performed on the blots using Bio-Rad Image Lab 4.0 software, 
to yield semi-quantitative results. P = Placebo, M = Molsidomine. Data expressed as mean ± SD; n=6 per group. 
Statistical analysis using 2-way ANOVA. Significances indicated are within group effects of time (black = 
Placebo, maroon = Molsidomine). (B) Representative Western blots for MPO from all four time points. Each 
row represents 1 Western blot. Ponceau S. staining was used as an internal loading control, after which 
samples were further normalised with an uninjured, untreated reference sample that was run on all gels (L). 
Numbers 1-6 represent individual samples in each treatment group. See Appendix V for representative 
Ponceau stains. 
5.4 Myogenic regulatory factor response to injury 
Western blots for MyoD and Myogenin total protein content were performed as an indication of 
muscle satellite cells proliferation and differentiation into myotubes, respectively. 
There was a main effect of treatment (ANOVA p = 0.05) to lower MyoD expression. Post-hoc tests 
revealed the significant difference between Placebo and treatment groups was present at day 5 only 
(Figure 5.4). In the Placebo group, MyoD content peaked at day 5 post-injury, while in the 
Molsidomine group, MyoD content was not significantly different from the earlier or the later time-
points.  
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Figure 5.4 Western blot quantification of total MyoD protein content as an indicator of satellite cell proliferation in 
crush-injured rat gastrocnemius muscle. (A) Densitometry was performed on the blots using Bio-Rad Image 
Lab 4.0 software to yield semi-quantitative results. Data expressed as mean ± SD; n=6 per group. ф = 
Molsidomine treatment effect. (B) Representative Western blots for MyoD on tissue lysates from all four time 
points. Each row represents 1 Western blot. Ponceau S. staining was used as an internal loading control, after 
which samples were further normalised with an uninjured, untreated reference sample that was run on all gels 
(L). Numbers 1-6 represent individual samples in each treatment group. See Appendix V for representative 
Ponceau stains. 
In the analysis of total myogenin protein content, a main effect of time (ANOVA p < 0.01) was 
revealed, this time, irrespective of treatment (Figure 5.5). Myogenin content was significantly lower 
on day 5 compared to day 3 for both groups. 
 
Figure 5.5 Quantification of total Myogenin protein content as an indicator of satellite cell differentiation in crush-
injured rat gastrocnemius muscle. (A) Densitometry was performed on the blots using Bio-Rad Image Lab 4.0 
software to yield semi-quantitative results. Data expressed as mean ± SD; n=6 per group. (B) Representative 
Western blots for Myogenin on tissue lysates from three time points. Each row represents 1 Western blot. 
Ponceau S. staining was used as an internal loading control, after which samples were further normalised with 
an uninjured, untreated reference sample that was run on all gels (L). Numbers 1-6 represent individual samples 
in each treatment group. See Appendix V for representative Ponceau stains. 
 
ф 
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5.5 The extent of fibrosis in regenerating muscle tissue: modulation of 
TGF-β signalling and fibronectin content. 
In terms of the extent of fibrosis after injury, representative images of collagen deposition are 
presented in Figure 5.6. Non-injured muscle shows relatively small amounts of collagenous tissue 
(Figure 5.6 A & D). Injured tissue shows far more collagen (Figure 5.6 B, C, E & F), especially in-
between newly formed fibers, which are indicated by centrally located nuclei (Figure 5.6 E & F). 
Molsidomine treatment seemed to not only reduce the amount of collagen, but it also seemed to 
have more uniformity to the collagen deposition, in that it seems to be organised around the new 
muscle bundles and not between the individual fibers, as seen in the Placebo group (Figure 5.6, F vs. 
E). 
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To enable statistical comparison, images were not only qualitatively analysed, but also subjected to 
automated image analysis. Quantitative data and statistical results (expressed relative to uninjured 
controls) are depicted in Figure 5.7. As expected, collagen content was significantly higher after 21 
days of recovery when compared to controls (an average of 437% and 295% higher for the Placebo 
and Molsidomine groups respectively). Mann-Whitney U tests confirmed that in Molsidomine 
treated animals, collagen deposition was significantly lower when compared to Placebo-treated 
animals, at 21 days after injury (p < 0.05, Figure 5.7). 
 
Figure 5.7 Collagen content at day 21 after injury. Images at 4x magnification were processed in ImageJ using the 
colour threshold function, and blue staining expressed as a percentage area of red staining. Data expressed as 
mean ± SD, relative to control (uninjured) values. n=6 per group. ф = Molsidomine treatment effect. 
TGF-β1 is involved in extracellular matrix synthesis and remodelling. There was a main effect of 
time (ANOVA p < 0.005), with total TGF-β1 protein content higher at the later time point of recovery. 
Additionally, a time-treatment interaction effect (p < 0.05), indicated that TGF-β1 increased 
significantly over time in the Placebo group only (Figure 5.8). Post-hoc testing confirmed the 
significant difference between the Placebo and treatment groups on day 21 (p = 0.01). 
ф 
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Figure 5.8 Quantification of total TGF-β1 protein content as an indicator of collagen formation in crush-injured rat 
gastrocnemius muscle. (A) Densitometry was performed on the blots using Bio-Rad Image Lab 4.0 software to 
yield semi-quantitative results. Data expressed as mean ± SD; n=6 per group. ф = Molsidomine treatment effect. 
(B) Representative Western blots for TGF-β1 on tissue lysates from 5 and 21 day post-injury time points. Each 
row represents 1 Western blot. Ponceau S. staining was used as an internal loading control, after which samples 
were further normalised with an uninjured, untreated reference sample that was run on all gels (L). Numbers 
1-6 represent individual samples in each treatment group. See Appendix V for representative Ponceau stains. 
Western blots for fibronectin revealed that the protein had been fragmented into isoforms of various 
molecular weights. Statistical analysis of the 31kDa fragment yielded no effects of treatment or time 
(results not shown). However, analysis of the 45 and 50kDa bands (which were measured together 
- Figure 5.9) showed a main effect of time (ANOVA p < 0.005), where the protein content was much 
lower 21 days post-injury. 
In fact, Placebo and Molsidomine groups were on average 104-fold and 274-fold lower, respectively, 
than their 5-day values. Mann-Whitney U tests confirmed that fibronectin content in the 
Molsidomine group was significantly lower than the Placebo group at the 21-day time point 
(indicated with a * in Figure 5.9). 
ф 
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Figure 5.9 Quantification of total Fibronectin (45 & 50 kDa) protein content as an indicator of ECM formation in 
crush-injured rat gastrocnemius muscle. (A) Densitometry was performed on the blots using Bio-Rad Image 
Lab 4.0 software to yield semi-quantitative results. Data expressed as mean ± SD; n=6 per group. ф = 
Molsidomine treatment effect. (B) Representative Western blots for Fibronectin on tissue lysates from 5 and 21 
day post-injury time points. Each row represents 1 Western Blot. Ponceau S. staining was used as an internal 
loading control, after which samples were further normalised with an uninjured, untreated reference sample 
that was run on all gels (L). Numbers 1-6 represent individual samples in each treatment group. See Appendix 
V for representative Ponceau stains. 
 
  
ф 
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Chapter 6: Discussion 
This thesis aimed to determine whether Molsidomine – a nitric oxide (NO) donor - would improve 
muscle regeneration after a damaging crush injury by modulating myogenesis, inflammation, 
and/or fibrosis. While muscle injury remains a common occurrence with debilitating symptoms 
(Smith et al., 2008; Gharaibeh et al., 2012), no globally effective therapies for regeneration have been 
developed. Current therapies target the related symptomatic complaints, by using the RICE 
principle, for example (Järvinen et al., 2007; Alessandrino & Balconi, 2013). Here the results, however, 
show that acute Molsidomine treatment modulates both the immune cell MPO release and the 
fibrotic response without having a large effect on MRFs - all of which suggest a potential therapeutic 
role for NO in reducing the side-effects of injury during muscle recovery. 
The first part of this study was to validate the delivery of NO to the injured muscle by Molsidomine. 
Quantification of NO is complicated by its high reactivity and short half-life, but the measurement 
of two products of NO metabolism, namely nitrite (NO2) and nitrate (NO3) is an effective indication 
of the presence of NO in a sample (Granger, 1996). We assayed tissue homogenates from our study 
groups 24 hours post-injury, approximately 1 hour after the second dose of either Placebo- or 
Molsidomine-infused jelly blocks. The resulting concentrations were below the lower detection 
limit. Further studies on the pharmacokinetics of Molsidomine and in particular its effect on NO 
metabolites in injured muscle are necessary. 
There is a wealth of research on inflammatory parameters after a crush injury (Rubinstein et al., 1998; 
Anderson, 2000; Darmani et al., 2004 a & b; Sun et al., 2010; Filippin et al., 2011 a & b), as well as in 
other types of injuries such as muscle strains (Tomazoni et al., 2012; Ramos et al., 2012; de Paiva 
Carvalho et al., 2013). In line with other studies using a crush injury model (Filippin et al., 2011 a & 
b; Myburgh et al., 2012), the injured tissue was characterised by a vast phagocytic cell infiltration 
into the injury site on 1, 3 and 5 days post-injury. By 5 days there was far less debris in the injured 
area indicating relatively rapid removal. Increased amounts of MPO in the tissue assist in the 
clearing of damaged tissue to prepare the site for regeneration (Smith et al., 2008). It, therefore, plays 
an important role.  
In human subjects, MPO is synthesised and released within the first hour after exercise-induced 
injury by both neutrophils and monocytes in  circulation, indicating activation of these cells (van de 
Vyver et al., 2015). Even after exhaustive exercise with no muscle damage, there is an acute response: 
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MPO activity is increased by about 40% in skeletal muscle (Belcastro et al., 1996). Here, the injury 
resulted in significantly elevated muscle MPO content even 5 days after (Figure 5.3). However, an 
undesirable side-effect of excessive MPO activity is the associated secondary damage to the muscle 
that may occur in the days following the initial injury (Lapointe et al., 2002; Tidball, 2008). Null 
mutation of MPO in mice resulted in a reduction of the neutrophil-mediated lysis of muscle cells in 
vitro and in an in vitro muscle/neutrophil co-culture (Nguyen et al., 2005). Our study is, to our 
knowledge, the first to evaluate the effects of Molsidomine on skeletal muscle regenerative processes 
in an experimental crush injury. Nonetheless, the drug has been utilised in other models of muscle 
disruption.  
In a rat model of hindlimb ischemia-reperfusion injury, Molsidomine reduced neutrophil infiltration 
upon reperfusion and decreased the number of necrotic fibers (Öztürk et al., 2009). In a large pig 
study, L-arginine treatment – an NO precursor – significantly reduced the extent of necrosis, 
neutrophil accumulation and MPO activity due to ischemia-reperfusion injury in myocutaneous 
flaps (Cordeiro et al., 1998). A study with the same model then found SIN-1 treatment to improve 
myocutaneous flap survival and to reduce the presence of MPO (Khiabani & Kerrigan, 2002). In the 
current crush injury model, Molsidomine slightly reduced the presence of MPO 5 days after injury 
by approximately 33% when compared to the Placebo group. In the ischemia-reperfusion studies 
just mentioned, exogenous NO also reduced neutrophil numbers in the injured limb, albeit at an 
earlier stage of injury. Taken together, the evidence suggests that Molsidomine treatment may 
reduce secondary damage associated with neutrophil invasion, although future studies quantifying 
the presence of neutrophils must still be done in the crush injury model.  
There are a few studies that make use of the drug as a long-term therapy for skeletal muscle 
pathologies, and with promising results. In α-sarcoglycan null mice – a severe model of muscular 
dystrophy – Molsidomine treatment for 1 month amplified macrophage recruitment and the 
effective clearance of debris. After 4 months of treatment, it reduced the inflammatory condition, 
fiber swelling and the number of phagocytic leukocytes. It was associated with reduced fibrosis and 
preservation of muscle tissue (Zordan et al., 2013). This illustrates a unique ability of Molsidomine 
to finely modulate the inflammatory response in dystrophic mice, which is comparable to its effects 
on MPO in our study, although there are obvious differences in model and timeline. 
There is far less research focused on fibrosis following an impact injury, especially research into 
potential anti-fibrotic therapies. For these reasons, fibrotic parameters were robustly assessed. 
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Nonetheless, there may be cross-talk between myogenesis and fibrosis. Therefore, myogenesis was 
also examined by Western blots for MyoD and myogenin protein content, two prominent myogenic 
markers.  
The main finding of our study was that Molsidomine significantly blunted the evidence of fibrotic 
scarring in the injured tissue 21 days after injury, despite administration of only two doses of the 
drug at 1 hour and 24 hours post-injury. In similar models of crush injury, fibrosis was generally 
evident 1, 2 and 4 weeks post-injury (Filippin et al., 2011 a & b). These researchers have shown, using 
L-NAME, that the inhibition of NO early on (2 hours) after crush injury significantly increased the 
formation of fibrotic tissue at day 7 (Filippin et al., 2011 a & b), which motivated the notion that 
endogenous NO is instrumental in the balance between scar formation and muscle repair. Our 
finding of a smaller amount of fibrosis complements and adds to their findings by showing the 
potential of additional, exogenous NO as a treatment. Even without quantification, reduced 
connective tissue is clearly evident in the histological sections (Fig 5.2, 5.3 & 5.7).   
The current histological finding was supported by a lower TGF-β1 and fibronectin protein content 
(p = 0.01 and p < 0.005, respectively) in muscle homogenates after Molsidomine treatment, compared 
to Placebo groups at the same time point i.e. 3 weeks post-injury. In a rat model of a rotator cuff tear, 
TGF- β signalling was upregulated at 2 and even at 6 weeks post-injury, with substantial collagen 
deposition in the injured area (Liu et al., 2014). In our model of a relatively severe injury, there is 
persisting fibrotic activity at the 21-day time point in the Placebo-treated rats, which suggests the 
muscle is still undergoing a wound healing response and effective remodelling is delayed.  
From the literature, it is known that NO reduces TGF-β bioactivity, including suppression of mRNA 
in models where activity is elevated. This resulted in decreased collagen synthesis in mesangial cells 
cultured in diabetic conditions (Craven et al., 1997). These findings were similar with both 
endogenously and exogenously generated NO.  Here, the range of values for TGF-β1 content was 
small at 5 days post-injury and not different between the Placebo and Molsidomine groups. It is 
important to note that the synthesis of connective tissue is part of the initial response to an injury in 
order to provide structural stability to the area. This may explain why there were no significant 
differences at this time. In another study, also in cultured mesangial cells, NO was found to down-
regulate connective tissue growth factor (CTGF), through decreased gene and protein expression 
(Keil et al., 2002). CTGF has been implicated as a downstream mediator of profibrotic TGF-β 
signalling and is, therefore, an important role-player in the development of various forms of fibrosis 
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(Gupta et al., 2000). Clearly, the literature is in support of the beneficial effect of an inhibition of TGF-
β expression, but an explanation for a delayed response (at 21 days) is not clear. It has been suggested 
that these two growth factors (CTGF & TGF-β) play a combined role in the regulation of skeletal 
muscle matrix turnover (Heinemeier et al., 2013), which would be a more long-lasting process, 
possibly with the involvement of fibroblasts. In vitro, SIN-1 (the active metabolite of Molsidomine) 
prevented fibroblast migration on fibronectin-coated plates (Sato et al., 2001). This supports the 
hypothesis that Molsidomine not only reduced fibronectin protein content 3 weeks post-injury 
(Figure 5.9) but may have also prevented fibroblast migration to the injury site and excessive 
connective tissue synthesis by these cells.  
MyoD is expressed by activated satellite cells that are proliferating (Ceafalan et al., 2014). Thus, more 
MyoD expression should be reflective of a better regenerative capacity. Rodent muscle cryo-lesions 
that were treated with low-level laser therapy (LLLT), showed significantly increased levels of 
MyoD and myogenin mRNA 4 days post-injury (Assis et al., 2013), indicating greater myogenesis. 
An unexpected result from our study was that Molsidomine treatment blunted the peak in satellite 
cell proliferation 5 days after injury (Figure 5.4). However, it is possible that Molsidomine caused 
either an earlier or a later peak in MyoD expression, but this cannot be confirmed with our 
experimental timeline. When our MPO results are considered (Figure 5.3), the reduced magnitude 
of immune-cell mediated inflammation associated with Molsidomine treatment may have indirectly 
reduced satellite cell proliferation and MyoD expression. It was mentioned earlier that Molsidomine 
may have reduced the extent of the secondary damage. However, myogenin is a marker for terminal 
differentiation of satellite cells (Ceafalan et al., 2014) and our results show that Molsidomine did not 
influence the normal myogenin expression profile. This implies that the myogenic response was not 
hindered in any way by Molsidomine treatment, but rather that it continued in an appropriate 
manner. MyoD and myogenin are transcription factors, that are expressed only in satellite cell nuclei. 
Immunohistochemical assessment of MyoD+ and myogenin+ nuclei would be useful for better 
interpretation.  
Although satellite cells are adult progenitors dedicated to the skeletal muscle niche, under extreme 
disturbance of the niche they can transdifferentiate into myofibroblasts, or fibroadipogenic 
progenitors (FAPs). C2C12 cells cultured for 8 hours with TGF-β1 decreased their expression of both 
MyoD and myogenin and differentiated into profibrotic myofibroblastic cells (Li et al., 2004). Our 
result of less fibrosis with Molsidomine treatment may thus, at least in part, be the result of a down-
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regulated TGF-β-dependent switch to a fibroblastic cell type. In mdx mice – another model of 
muscular dystrophy - Molsidomine improved fibrotic parameters by reducing FAP numbers and 
subsequently reducing adipose tissue deposition, as well as reducing collagen expression (Cordani 
et al., 2014). Importantly, this study recognised a mechanism for Molsidomine’s action, where it 
down-regulated peroxisome proliferator-activated receptors gamma (Pparγ1) through induction of 
miR-27b, which reduced adipogenesis in dystrophic muscle. The latter finding is valuable, as it may 
be likely that NO acts through a similar pathway to modulate fibrotic signalling. By integrating our 
results with the known literature, specifically the in vitro studies, it is clear that NO elicits effects on 
all of our measured parameters – namely myogenesis, inflammation, and fibrosis – individually 
rather that the first effect having a knock-on effect on the subsequent processes. We have 
summarised the identified targets of Molsidomine in Figure 6.1. 
 
 
Figure 6.1 Summary of Molsidomine’s effects after an acute impact injury. This diagram depicts the normal progression 
of skeletal muscle healing after an impact injury in a way that is relevant to the results of this thesis. The proposed 
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actions of Molsidomine (MOLS) are shown in red text, and indicate the potential targets of the drug as were 
elucidated by our study. 
In various other models, SIN-1 has been used as a therapeutic agent based on its ability to improve 
blood flow. Systemic delivery of SIN-1 reduced chronic pain in a rat model of post-ischemic, 
neuropathic pain. The treatment effect was greater at 2 days post-ischemia than at 7 days (Xanthos 
& Coderre, 2008). In a similar model, even topically applied NO-donors increased microvascular 
perfusion to the hind-paw, as measured using the Doppler technique (Laferrière et al., 2014), and in 
an earlier study, 6-hour preincubation with SIN-1 protected endothelial cells against cellular injury 
by TNF-α and increased their viability (Polte et al., 1997). This could imply that SIN-1 might protect 
the capillaries during the destruction phase of injury, resulting in more perfusion to the damaged 
area and ultimately, better repair. It has also been shown that NO prevents apoptosis in some cells 
through the inactivation of active caspases and protects the mitochondrial membrane against 
depolarization (Zech et al., 2003). It seems then, that future studies should investigate further the 
protective effects that Molsidomine might elicit on the microcirculation after an injury.  
In conclusion, we report here for the first time that NO reduces the fibrotic profile after an impact 
injury to skeletal muscle, whilst also modulating the inflammatory response and maintaining a 
proper myogenic response in treated rats. The mechanism by which NO reduced fibrosis was 
through a reduction of TGF-β1 signalling and a subsequent decrease in collagen deposition, as well 
as reduced fibronectin levels, 3 weeks after injury. Moreover, we have identified a novel role for the 
NO-donor, Molsidomine, which has previously been reported to benefit dystrophic muscles.  
Application 
Our study indicates that Molsidomine may be suitable for the acute treatment of impact injuries in 
otherwise healthy muscle. Molsidomine has a good safety and tolerability profile in humans (Messin 
et al., 2006) and therefore, clinical trials of Molsidomine in the context of acutely injured humans 
subjects may be possible in the near future. In a review of sports-related injuries in humans, 21 days 
post-injury was described as the time point at which either effective remodelling or fibrosis is 
underway (Jarvinen et al., 2005) and the current study provides evidence within that time frame. 
Furthermore, muscle TGF-β1 and fibronectin mRNA were upregulated as early as 6 hours after a 
moderate eccentric kicking-exercise protocol in humans (Heinemeier et al., 2013), suggesting that 
even in human subjects, early treatment is warranted. 
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Appendices 
Appendix I: HEMATOXYLIN & EOSIN STAINING 
H & E staining reagents 
Mayer’s hematoxylin: Commercially available Mayer’s Hematoxylin (Sigma-Aldrich, Cat. #: 
MHS80, USA) was filtered through Whatman’s number 2 filter paper before each stain and placed 
in two Coplin jars in the auto-staining apparatus. The stock was kept at room temperature. 
Eosin: Commercially available Alcoholic Eosin (Leica Biosystems, Cat. #: 3801600E, UK) was further 
diluted in 95% Ethanol and placed in a Coplin jar in the auto-staining apparatus. The stock was kept 
at room temperature. 
Scott’s tap water (blueing agent): 1% Magnesium Sulfate and 0.07% Sodium Bicarbonate were 
dissolved in 900mL of tap water, the solution was titrated to a pH of 8, using HCl, and made up to 
1000mL. The fresh working solution was then placed in a Coplin jar (fresh every time) in the auto-
staining apparatus. The stock was kept at room temperature. 
Xylene (clearing agent): Commercially available Xylene (Merck, Cat. #: 1086619190, South Africa) 
was kept at room temperature in a covered container and used as required. 
Ethanol: 100% Ethanol and 95% Ethanol in dH2O were kept at room temperature and used for 
dehydration steps in Coplin jars in the auto-staining apparatus. 
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H & E staining protocol 
1. Remove frozen tissue sections from the freezer and allow to thaw at room temperature for 5 
minutes. 
2. Place slides into the auto-staining apparatus and set the timer to 120 seconds per reagent/jar. 
3. Staining proceeds automatically as follows: 
a) Tap water  
b) Two changes of Mayer’s hematoxylin  
c) Warm tap water (26°C)  
d) Scott’s tap water  
e) Tap water  
f) 5% Eosin in 95% Ethanol  
g) Tap water  
h) 95% Ethanol  
i) 100% Ethanol  
j) Final clearance in Xylene (leave in container for 5 minutes) 
k) Mount in a resinous mounting medium 
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Appendix II: MASSON’S TRICHROME STAINING 
Masson’s staining reagents  
Bouin's solution (fixation agent): 75mL picric acid (saturated), 25mL Formaldehyde (37-40%) and 
5mL Glacial acetic acid were mixed well to make a working solution, which was stored in a fume 
hood at room temperature. 
Weigert's iron hematoxylin solution: Stock Solution A consisted of 1g Weigert’s hematoxylin in 
100mL of 95% Ethanol. Stock Solution B consisted of 4mL of 29% Ferric chloride in dH2O, 95mL 
dH2O and 1mL of concentrated Hydrochloric acid. Equal parts of Stock A and Stock B were mixed 
together for the working hematoxylin solution, which was stored at room temperature for a 
maximum of 3 months. 
Biebrich scarlet-acid fuchsin solution: 90mL of 1% aqueous Biebrich scarlet was mixed with 10mL 
of 1% aqueous Acid fuchsin and 1mL glacial Acetic acid. The solution was stored at room 
temperature. 
Phosphomolybdic-Phosphotungstic acid solution: 25mL of 5% Phosphomolybdic acid was mixed 
with 25mL of 5% Phosphotungstic acid and the stock stored at room temperature. 
Aniline blue solution: 2.5g of Aniline blue powder was mixed with 2mL of glacial acetic acid and 
100mL of dH2O. The solution was stored at room temperature. 
1% Acetic acid solution: 1mL of glacial acetic acid was mixed in 99mL of dH2O and stored at room 
temperature. 
Xylene (clearing agent): Commercially available Xylene (Merck, Cat. #: 1086619190, South Africa) 
was kept at room temperature in a covered container and used as required. 
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Masson’s staining protocol 
1. Fix tissue in Bouin's solution for 1 hour at 56°C to improve staining quality. 
2. Rinse running tap water for 5-10 minutes to remove the yellow colour. 
3. Stain in Weigert's iron hematoxylin working solution for 10 minutes. 
4. Rinse in running warm (26°C) tap water for 10 minutes. 
5. Wash in dH2O for 1 minute. 
6. Stain in Biebrich scarlet-acid fuchsin solution for 10-15 minutes. 
7. Wash in dH2O for 1 minute. 
8. Differentiate in Phosphomolybdic-Phosphotungstic acid solution for 10-15 minutes or until 
collagen is not red. 
9. Transfer sections directly (without rinse) to aniline blue solution and stain for 5-10 minutes. 
10. Rinse briefly in dH2O and differentiate in 1% acetic acid solution for 2-5 minutes. 
11. Wash in dH2O for 1 minute. 
12. Dehydrate very quickly through 95% ethyl alcohol, absolute ethyl alcohol (these step will 
wipe off Biebrich scarlet-acid fuchsin staining) and clear in xylene. 
13. Mount with resinous mounting medium. 
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Appendix III: TISSUE LYSATE PREPARATION AND SDS-PAGE  
Tissue Lysate Preparation 
Approximately 40mg (Western blotting) or 120mg (Nitrite/Nitrate assay) of injured muscle tissue 
was sectioned and collected using a cryostat (Leica CM1860 UV, Leica Biosystems Nussloch GmbH, 
Germany) at -25℃. Samples were kept in 2.0mL reaction vials (Eppendorf, Germany) and 550µL of 
Lysis Buffer (Western blotting) or 1.1mL of 1% phosphate-buffered saline, or PBS, in dH2O 
(Nitrite/Nitrate assay) was added to each tube. Samples were then homogenised on ice using a 
handheld homogenizer (Polytron PT2100, Kinematica AG, Switzerland) at 30 000rpm. After each 
sample had been homogenised, the homogenizer was rinsed twice in dH2O and once in 1% PBS in 
dH2O in order to remove any residual tissue from the blades, and any excess droplets were shaken 
off into a glass beaker. Homogenised samples were then centrifuged at 10 000g for three minutes 
(Spectrafuge 24D, Labnet Int., Inc., USA), after which the supernatant was removed and placed on 
ice for analysis or stored at -80°C until later analysis. 
Measurement of Sample Protein Concentration 
For Western blotting, 30µg of protein per sample was loaded into the wells, thus all samples had to 
be diluted so that equal amounts of protein were loaded. A protein standard calibration curve was 
generated using bovine serum albumin (BSA) (Bovine Serum Albumin Fraction V, Roche, USA) in 
lysis buffer, ranging from 0mg/mL to 6mg/mL. For the Nitrite/Nitrate assay, samples were all 
equalised and diluted down to the sample with the lowest protein concentration and a protein 
standard calibration curve was generated using Bovine serum albumin (BSA) (Bovine Serum 
Albumin Fraction V, Roche, USA) in 1% PBS in dH2O, also ranging from 0mg/mL to 6mg/mL.  
For both protocols, protein concentrations were measured using a commercial Bicinchoninic acid 
(BCA) kit (Pierce ® BCA protein assay, Thermo Fischer Scientific, USA). The assay was performed 
on a 96-well plate (PS microplate, Greiner Bio-One, USA) with 200µL BCA added to 10µL of the 
sample or standards. All samples and standards were loaded in duplicate. The absorbance of BCA 
was measured at 595nm in a plate reader (EL-500 Universal Microplate reader, Bio-Tek Instruments 
Inc, USA). Concentrations of the samples were calculated by KC Junior software, using the standard 
calibration curve on a Dell desktop computer (Dell, USA). 
SDS-PAGE and Western Blot Reagents 
RIPA buffer: 50mM Tris HCl (pH 7.5), 150mM NaCl, 1mM EDTA, 1% vol/vol nonidet p40, 0.25% 
weight/vol Sodium deoxycholate in dH2O. Kept at 4°C. 
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Lysis buffer: RIPA buffer, supplemented with 0.01mg/mL phosphatase inhibitor (Roche, Cat. #: 
04 906 837001), 0.02mg/mL protease inhibitor (Roche, Cat. #: 04 693 116001), 100ng/mL pepstatin 
(Sigma-Aldrich, Cat. #: P5318, USA). Used immediately or stored at -20°C. 
Gels: Gels were hand-cast immediately before running the SDS-PAGE. The following reagent 
volumes were sufficient for the casting of two gels. 
Table I SDS-PAGE gel preparation. Below, the reagent volumes used for stacking and separating gels. 
Reagents Stacking Gel (4%) Separating Gel (8%) Separating Gel (12%) 
dH2O 3mL 6.5mL 8mL 
Tris (pH 6.8) 1.25mL - - 
Tris (pH 8.8) - 3.75mL 3.75mL 
40% Acrylamide 670µL 4.5mL 3mL 
10% SDS 25µL 150µL 150µL 
10% APS 25µL 85µL 85µL 
TEMED 5µL 12µL 12µL 
 
 
Running Buffer (1%): 0.025M Tris, 0.192M Glycine and 0.1% SDS (w/v) were mixed into 1000mL of 
dH2O and stored at room temperature.  
Transfer Buffer (1%): 0.025M Tris and 0.192M Glycine were dissolved in dH2O and 20% methanol 
added to make a 1% working solution before use. Kept at room temperature. 
Tris-buffered saline in Tween (TBS-T: 1%): 50mM Tris, 150mM NaCl and 0,1% Tween-20® were 
mixed into 900mL of dH2O and titrated to a pH of 8.3 using HCl. It was made up to 1000mL and 
stored at room temperature. 
Ponceau S: 0.1g of Ponceau S. (Sigma-Aldrich, Cat. #: P3504, USA) was dissolved in 1mL of 100% 
(v/v) acetic acid and made up to 100mL with distilled water. The Ponceau S. stain was stored in a 
glass bottle at 4°C. 
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Ammonium Persulfate: APS (Sigma-Aldrich, Cat. #: A3678, USA) was made up to 10% (w/v) in dH2O 
and stored at -20°C. 
Stripping buffer: 0.2M Glycine, 0.1% SDS, 1% Tween-20® were mixed into 800mL of distilled water 
and titrated to a pH of 2.2 using HCl, then made up to 1000mL and stored at room temperature. 
Membrane Stripping Protocol 
Some membranes were re-probed for proteins at different molecular weights. Membranes were 
washed for 2 x 10 minute changes in 1% TBS-T and then incubated twice for 15 minutes in stripping 
buffer, with gentle shaking. Membranes were then vigorously rinsed in two changes of 1% TBS-T, 
followed by a 15 minute was with shaking. Membranes were then blocked in 5% fat-free milk 
(Parmalat SA (Pty) Ltd., South Africa) for one hour at room temperature and then treated with the 
appropriate primary and HRP-linked secondary antibodies.  
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Appendix IV: PRIMARY AND SECONDARY ANTIBODIES FOR WESTERN 
BLOTTING 
Table II List of primary and secondary Western blot antibodies as well as the respective dilutions. 
Primary Antibody  Secondary Antibody  
Rabbit polyclonal anti-MyoD1 
(Sigma-Aldrich, Cat. # SAB1410813, USA) 
1:1000 
Anti-rabbit HRP-linked secondary Ab 
(Cell Signaling, Cat. # 7074S)  
1:15 000 in 5% fat-free milk in TBS-T 
Rabbit polyclonal anti-Myogenin 
(Sigma-Aldrich, Cat. # SAB1305721, USA) 
1:1000 
Same as above 
Rabbit polyclonal anti-Myeloperoxidase 
(Abcam, Cat. # ab45977, UK) 
1:1000 
Same as above 
Rabbit polyclonal anti-TGFβ1 
(Santa Cruz, Cat. # sc-146, USA) 
1:1000 
Same as above 
Mouse monoclonal anti-Fibronectin 
(Santa Cruz, Cat. # sc-80982, USA) 
1:1000 
Anti-mouse HRP-linked secondary Ab 
(Cell Signaling, Cat. # 7076S)  
1:20 000 in 5% fat-free milk in TBS-T 
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Appendix V: PONCEAU IMAGES FOR EACH SDS-PAGE 
Myeloperoxidase Gels 
 
Figure I Ponceau stained gels prior to Western blotting for MPO. Gels used for MPO Western blots at 1, 3, 5 and 21-
day time points. L – indicates the lane containing the loading control reference sample, which was run on every 
single gel. The protein ladder is in the left-most lane, where the 75 kDa protein standard is indicated. 
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MyoD Gels 
 
Figure II Ponceau stained gels prior to Western blotting for MyoD. Gels used for MyoD Western blots at 3, 5 and 21-
day time points. L – indicates the lane containing the loading control reference sample, which was run on every 
single gel. The protein ladder is in the left-most lane, where the 37 kDa protein standard is indicated. 
Myogenin Gels 
 
Figure III Ponceau stained gels prior to Western blotting for Myogenin. Gels used for Myogenin Western blots at 3, 5 
and 21-day time points. L – indicates the lane containing the loading control reference sample, which was run 
on every single gel. The protein ladder is in the left-most lane, where the 37 kDa protein standard is indicated. 
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TGF-β Gels 
 
Figure IV Ponceau stained gels prior to Western blotting for TGF-β. Gels used for TGF-β Western blots at 5 and 21-
day time points. L – indicates the lane containing the loading control reference sample, which was run on every 
single gel. The protein ladder is in the left-most lane, where the 37 kDa protein standard is indicated 
 
Fibronectin Gels 
 
Figure V Ponceau stained gels prior to Western blotting for fibronectin. Gels used for fibronectin Western blots at 5 
and 21-day time points. L – indicates the lane containing the loading control reference sample, which was run 
on every single gel. The protein ladder is in the left-most lane, where the 75 kDa protein standard is indicated. 
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